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ABSTRACT 
 
Autoimmune diseases are believed to arise from a combination of genetic and 
environmental factors that affect normal function of immune cells. In this thesis, we 
studied the functional role of genetic variants, in peripheral blood cells, that relate to 
rheumatoid arthritis (RA) and myositis by gene expression profiling. 
 
Genome wide association studies have identified numerous susceptibility loci for 
autoimmune diseases, however, the precise mechanisms of how these loci lead to 
increased risk of autoimmunity remain mostly unknown. We therefore aimed to 
increase our understanding of the involvement of the susceptibility loci PTPN2, 
PTPN22 and HLA-DRB1 in the pathogenesis of RA. For the PTPN2 locus, we show 
that the long non-coding RNA (lncRNA) LINC01882 encoded on this locus can be 
linked to RA. We found that the genetic variants in the PTPN2 locus are associated 
with the expression of several lncRNAs, but not with the expression of PTPN2. By 
silencing LINC01882 in Jurkat T cells, we identified that LINC01882 might play a role 
in T-cell activation by regulating IL-2 levels, an important cytokine in RA. In addition, 
we show a new role for the PTPN22 risk allele in the context of RA through the 
generation of CD4+ T cells with cytotoxic characteristics. We found that genes related 
to T-cell survival and cytotoxic T-cell differentiation were differentially expressed 
between PTPN22 risk and non-risk allele carriers. This led us to identify an increased 
frequency of EOMES+CD4+ T cells in healthy individuals carrying the PTPN22 risk 
allele. Furthermore, we identified a difference in the expression of HLA-DRB1 and 
certain HLA-DQ genes between healthy individuals carrying RA HLA-DRB1 risk 
(*04:01) and non-risk (*15:01) alleles. These differences in gene expression were 
observed in different cell types, including CD4+ and CD8+ T cells. This data suggests 
that HLA-DRB and HLA-DQ levels, and potentially their corresponding proteins, might 
support loss of immune tolerance in RA patients carrying HLA-DRB1*04:01 alleles. 
 
In addition, we aimed to differentiate involvement of CD4+ and CD8+ T cells in the 
myositis subgroups, polymyositis (PM) and dermatomyositis (DM), by studying gene 
expression. We found two genes that were differentially expressed in CD4+ T cells of 
patients with PM compared to DM, whereas we identified 176 genes that were 
differentially expressed in CD8+ T cells of patients with PM compared to DM. Several 
of these genes were related to lymphocyte migration and regulation of T-cell 
differentiation. These results add to the evidence that different immune mechanisms are 
involved in patients with PM compared to patients with DM. 
 
In summary, this thesis presents several new mechanisms for the RA susceptibility loci 
PTPN2, PTPN22 and HLA-DRB1. As these susceptibility loci are shared between 
several autoimmune diseases, these results can be implicated in the pathogenesis of 
other autoimmune diseases as well. We further suggest that different immune 
mechanisms are involved in subgroups of RA and myositis patients. These results could 
ultimately lead to the identification of more specific therapeutic targets for different 
autoimmune diseases.  
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1 INTRODUCTION 
1.1 GENE EXPRESSION AND REGULATION 
All cells in a multicellular organism contain the same genetic information, however, 
only a fraction of the genes are expressed in each cell type. This is mainly determined 
by the genetic information contained in the DNA. This genetic information includes 
both protein-coding genes and non-coding genes that can regulate the expression of 
protein-coding genes. Gene expression is a tightly controlled process and any alteration 
in gene expression might lead to the development of diseases. 
1.1.1 Gene expression 
Gene expression is a tightly controlled process. It involves the transcription of protein-
coding genes and many non-coding genes into RNA transcripts by RNA polymerase II 
(RNA pol II). The RNA pol II and its associated general transcription factors (TFs) 
assemble at the core promoter, that typically stretches a region of approximately 80 
nucleotides around the transcription start site, and initiate transcription. The three most 
abundant core promoter motifs are the TATA-box, initiator motif and downstream 
promoter element1. Apart from these distinct motifs, core promoters often overlap with 
regions with high density of CpG dinucleotides, called CpG islands. In general, 
methylation of CpG islands is associated with the repression of gene expression. In 
addition, active core promoters exhibit highly dynamic nucleosomes containing certain 
histone variants, which make them accessible for the transcription machinery. 
Furthermore, active core promoters are associated with specific epigenetic 
modifications of histones. 
 
Transcription is extremely weak in the absence of regulatory elements that are distinct 
from the core promoter. These regulatory elements, known as enhancers, can regulate 
gene expression by binding TFs that recruit transcriptional cofactors. Cofactors, either 
activators or repressors, are often involved in post-translational modifications of the 
transcription machinery and surrounding nucleosomes. It is suggested that enhancers 
have preferences towards certain promoters2. Large clusters of regulatory elements 
form super-enhancers. These super-enhancers are enriched for the binding of cell type 
specific TFs and therefore play a critical role in defining cell identity3. In addition, 
super-enhancers are often found near genes that have cell type specific functions4. 
 
Like promoters, enhancer activity is also under the control of epigenetic modifications. 
Recent studies have revealed that inactive enhancers are characterized by the presence 
of histone 3 lysine 27 tri-methylation (H3K27me3). During activation, the H3K27me3 
modification will be replaced by H3K27 acetylation (H3K27ac). In addition, poised 
enhancers are marked by H3K27me3 and H3K4 mono-methylation (H3K4me1)5. 
Moreover, DNA methylation is also involved in the regulation of enhancer activity. 
Inactive enhancers are characterized by DNA methylation, whereas active enhancers 
are characterized by DNA hypomethylation6. Interestingly, 5-hydroxymethylcytosine, 
the oxidized form of 5-methylcytosine, appears to correlate with active enhancers as it 
prevents the methylation of the cytosine7. 
 2 
Interactions between promoters and enhancers are independent of their relative distance 
and can even occur between different chromosomes8. In order to facilitate interactions 
between distant loci, the genome is organized in three-dimensional structures. Each 
chromosome occupies a discrete territory within the nucleus and each chromosome can 
be further organized into loop domains and compartmental domains. Loop domains 
depend on the activity of architectural proteins such as CCCTC-binding factor (CTCF) 
and cohesin, whereas compartmental domains are independent of these proteins and 
reflect transcriptional and chromatin states9. CTCF is a zinc-finger protein composed 
of multiple domains that can interact with DNA, RNA and proteins to control chromatin 
loops. These loops represent topologically structures wherein transcription takes 
place10. Next to mediating interactions between promoters and enhancers11, CTCF can 
play a role in alternative splicing and recombination12,13. Disruption of CTCF binding 
sites can affect gene expression and lead to diseases14-16. 
1.1.2 RNA splicing 
During transcription, the non-protein-coding introns are removed from the pre-
messenger RNA (mRNA) and the protein-coding exons are joined to form the mRNA. 
This process is called pre-mRNA splicing and is catalyzed by the spliceosome 
machinery, which consists of distinct small nuclear ribonucleoproteins. The 
spliceosome recognizes several motifs of the pre-mRNA, such as the splice sites and 
branch point. The splice sites are generally represented by the dinucleotides GU at the 
5’ end of the intron and AG at the 3’ end of the intron. The branch point is about 18 - 
40 nucleotides upstream of the 3’ splice site. Pre-mRNA splicing is a two-step reaction. 
In the first step, the branch point sequence carries out a nucleophilic attack on the 5’ 
splice site. In the second step, the 5’ exon initiates a second nucleophilic attack on the 
3’ splice site, resulting in the release of the intron as a RNA lariat and ligation of the 
exons17. 
 
For about 95% of the human genes, splicing leads to different mature mRNA products 
and proteins18,19. This process is known as alternative splicing and increases the mRNA 
diversity in complex organisms. Alternative splicing is controlled by the occurrence of 
cis-regulatory RNA elements, which can act as enhancers or silencers. These RNA 
elements can in turn recruit trans-acting proteins, such as splicing factors. Types of 
alternative splicing include the use of alternative 5’ and 3’ splice sites, cassette exons, 
retained introns and mutually exclusive exons20. 
 
Alternative splicing is a tightly regulated process. It can be affected by factors such as 
splicing factors, pre-mRNA secondary structure and chromatin organization. In 
addition, the elongation rate of transcription by RNA pol II, affected by the GC content 
of a gene, DNA methylation density, histone marks and long terminal repeats, can 
regulate alternative splicing20-22. Transcription at lower rates may increase the 
recognition of splice sites and leads to alternatively spliced variants23,24. Moreover, 
alternative splicing can be a cell type specific process. For example, the transmembrane 
phosphatase CD45, involved in regulating proximal antigen receptor-mediated 
signaling, undergoes extensive alternative splicing of the cassette exons 4, 5, and 6 in 
response to T-cell activation. Upon T-cell activation, the expression of CD45RO (skips 
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exon 4, 5 and 6) is increased and the expression of CD45RA (contains only exon 4) is 
decreased. Skipping of the three exons reduces the phosphatase activity of CD4525. 
 
Alternative splicing may also create isoforms that contain premature termination 
codons, which are targeted for degradation by the nonsense-mediated decay (NMD) 
pathway. The NMD pathway degrades transcripts by removing the 5’ cap and 
subsequent 5’ and 3’ digestion26. However, it has become apparent that the NMD 
pathway is also important for other cellular transcripts to regulate expression levels in 
a post-transcriptional manner27. Approximately 10% of the mRNAs in mammalian 
cells appear to be targets for NMD27. 
1.1.3 Non-coding RNAs 
Non-coding RNAs (ncRNAs) have been known for many years. The first ncRNAs, 
such as ribosomal RNAs (rRNAs) and transfer RNAs (tRNAs), were already described 
in the 1950s28,29. Since then, a few more ncRNAs, including small nuclear RNAs 
(snRNAs) involved in splicing and small nucleolar RNAs (snoRNAs) involved in the 
modification of rRNAs, have been discovered. In 2001, after publishing the first draft 
of the human genome30,31, it became evident that only a small fraction of the human 
genome encodes for proteins32. More recently, a study revealed that 80.4% of the 
human genome has a biochemical function (RNA- and/or chromatin-associated)33. 
These studies have changed our view on the human genome and highlighted the 
importance of ncRNAs. They are involved in a wide range of processes, such as X-
chromosome inactivation and epigenetic regulation34,35. However, the function of most 
identified ncRNAs remains to be characterized. Dysregulation of ncRNAs has been 
implicated in numerous diseases36-40. ncRNAs can be classified into small ncRNAs (< 
200 nucleotides) or long ncRNAs (lncRNAs (> 200 nucleotides)). 
1.1.3.1 Small non-coding RNAs 
The most well studied group of small ncRNAs are microRNAs (miRNAs). miRNAs 
are 20 - 22 nucleotides in length and regulate gene expression. The first miRNA was 
reported in C. elegans in 199341. The small ncRNA lin-4 was found to be 
complementary to the 3’ UTR of lin-1441 and suppressed accumulation of the LIN-14 
protein42. In 2000, another miRNA, named let-7, was reported to be important during 
the development of C. elegans43. Soon thereafter, it was discovered that these miRNAs 
were highly conserved across phylogeny from worms to humans44,45, suggesting that 
miRNAs have a more general role in biology. This led to the identification of over 1900 
annotated miRNAs in the human genome (miRBase). Moreover, 60% of the human 
protein-coding genes are targets of miRNAs46. 
 
miRNAs are embedded in long primary transcripts that are transcribed by RNA pol II. 
The majority of miRNAs are localized within introns of protein-coding and lncNRA 
transcripts, but some are localized within exons47. In addition, several miRNAs are 
often in close proximity to each other, but can be individually regulated at post-
transcriptional level48. Following transcription, the pri-miRNA, containing a hairpin 
structure where the miRNA is embedded, is processed by the RNase III endonuclease 
Drosha and its cofactor DGCR8. This complex cuts the pri-miRNA into a pre-miRNA 
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with intact hairpin structure and a two nucleotide long 3’ overhang. The pre-miRNA is 
exported into the cytoplasm by exportin 5. In the cytoplasm, the RNase III 
endonuclease Dicer binds to the pre-miRNA, with a preference for pre-miRNAs 
containing a two nucleotide long 3’ overhang, and cleaves it close to the loop structure 
forming a small RNA duplex. This duplex is subsequently loaded onto an AGO protein 
to form the RNA induced silencing complex (RISC). It removes the passenger strand 
to form the mature RISC. The miRNA guides the mature RISC to the miRNA binding 
sites, which are usually located in the 3’ UTR of mRNAs. This causes either 
degradation (perfect match) or repression (imperfect match) of the mRNA47. These 
processes are tightly regulated and dysregulation is associated with diseases, such as 
cancer, neurodevelopmental disorders and autoimmune disorders36-38. 
 
Other small ncRNAs include small interfering RNAs (siRNAs) and PIWI-interacting 
RNAs (piRNAs). siRNAs are derived from exogeneous sources, such as viruses and 
transposons, and function in a similar way as miRNAs to degrade mRNAs. In addition, 
siRNAs can be used to induce short-term silencing of genes in functional experiments49. 
piRNAs are a distinct class of 23 - 30 nucleotide long RNAs that form complexes with 
PIWI proteins to silence retrotransposons and other genetic elements in germ line cells 
via mainly epigenetic mechanisms50,51. Although it has long been thought that piRNAs 
are restricted to germ line cells, recent studies have identified piRNAs in the 
mammalian brain52 and human plasma53. More studies are needed in order to fully 
elucidate the role of piRNAs in humans. 
1.1.3.2 Long non-coding RNAs 
The majority of ncRNAs belong to the group of lncRNAs. lncRNAs are longer than 
200 nucleotides and can be transcribed by RNA pol II, 5’ capped, 3’ polyadenylated 
and spliced. It has been shown that lncRNAs can regulate gene expression through 
diverse mechanisms. The first lncRNA was discovered in the late 1980s. Two imprinted 
genes localized to the same cluster at mouse chromosome 7, the paternally expressed 
Igf2 and the maternally expressed H19, were identified54,55. H19 was unusual as it lacks 
translation even though it contained small open reading frames. Although H19 is not 
translated into a protein, it was found to play a crucial role in embryonic development56. 
A couple of years later, the lncRNA Xist was discovered in the X-inactivation center 
important for initiating X-chromosome inactivation. In addition, the lncRNA Xist can 
be transcriptionally repressed by the lncRNA Tsix, an antisense transcript that overlaps 
with the gene of Xist57. In the early 2000s, it was discovered that a large number of 
transcriptionally active regions of human chromosome 21 and 22 were not mapping to 
any known protein-coding gene58,59. After the human genome was sequenced30,31, it 
became evident that most of the genome, protein-coding or not, was actually 
transcribed32. 
 
Previous mentioned findings were supported by findings from the consortia FANTOM 
and ENCODE. The FANTOM consortium determined the base sequences, assigned 
functional annotations to a set of 60,770 full-length mouse complementary DNA 
sequences and identified that ncRNAs are a major component of the mouse 
transcriptome60. Later, utilizing a technology named cap-analysis of gene expression 
(CAGE), they revealed that antisense transcription is widespread in the mammalian 
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genome and might contribute to the regulation of gene expression61. The CAGE 
technique sequences pol II transcribed RNAs that are capped on the 5’ end to map the 
transcription start sites and promoters62. In their latest project63, they generated an atlas 
of 27,919 human lncRNAs found in major human primary cells and tissues64. They 
revealed that most of the intergenic lncRNAs originate from enhancers rather than from 
promoters64. In addition, they suggest that lncRNAs are involved in multiple diseases. 
They found that lncRNAs that overlap with disease-associated single nucleotide 
polymorphisms (SNPs) are specifically expressed in cell types relevant to the disease64 
(discussed in more detail below). The FANTOM consortium now launched a new 
project to systematically elucidate the function of lncRNAs in the human genome. 
 
The ENCODE consortium aimed to identify all functional elements in the human 
genome by utilizing high-throughput methods, such as RNA-seq, ChIP-seq and ATAC-
seq. They revealed that a total of 74.7% of the human genome was transcribed into 
RNA65. In addition, the majority of lncRNAs (92%) was not translated66. Furthermore, 
they found that lncRNAs are generated through similar pathways as protein-coding 
genes67. However, expression of lncRNAs is more cell type specific. Also, lncRNAs 
were found to be predominantly localized to chromatin structures and the nucleus67. In 
addition, lncRNAs do not seem to be conserved, however, their promotor regions are 
almost as conserved as protein-coding gene promotors67. 
 
Although these studies have indicated the importance of lncRNAs, the functional 
mechanisms of the majority of lncRNAs is not clear. lncRNAs have been identified to 
act through diverse mechanisms. They can interact with DNA, RNA, chromatin and 
proteins. lncRNAs can act as scaffolds to form protein complexes68. lncRNAs can also 
act as guides to target chromatin remodeling complexes to the genome. lncRNAs can 
form chromosomal loops and mediate inter-chromosomal interactions. Many lncRNAs 
serve as precursors for small ncRNAs, in particular siRNAs. lncRNAs can also act as 
competing endogenous RNAs or miRNA sponges that indirectly regulate gene 
expression levels69,70. As an example, the level of the tumor suppressor gene PTEN can 
be modulated by its pseudogene PTENP1 as they both contain binding sites for the 
same miRNAs71. Therefore, lncRNAs can influence many cellular processes, such as 
chromatin remodeling, transcription, splicing and translation. The following examples 
demonstrate the flexibility of regulatory lncRNAs. 
 
Chromatin remodeling 
lncRNAs are involved in epigenetic modifications, including histone acetylation, 
histone methylation and DNA methylation. For example, the before mentioned 
lncRNA Xist coats the X-chromosome to recruit chromatin remodeling complexes to 
induce silencing. In more detail, Xist recruits the polycomb repressive complex 2 
(PRC2), including the histone methyl transferase EZH2, which catalyzes formation of 
the repressive histone mark H3K27me3 and silences the X-linked genes (Figure 1)72. 
Moreover, the antisense transcript Tsix suppresses the expression of Xist through the 
induction of DNA methylation. Tsix interacts with the DNA methyl transferase 
DNMT3a and is recruited to the promoter of Xist to methylate it73. Another example is 
the lncRNA HOTAIR, encoded on the chromosome 12 HOXC locus. The 5’ end of 
HOTAIR recruits the PRC2 complex to the HOXD locus on chromosome 2 to silence it 
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by catalyzing the formation of H3K27me3. It has been suggested that HOTAIR recruits 
PRC2 to induce silencing of multiple genes68. In addition, the 3’ end of HOTAIR 
interacts with the CoREST/REST complex, including the histone demethylase LSD1, 
which demethylates H3K4me2 (a marker of actively transcribed regions). Thus, 
HOTAIR serves as a scaffold to assemble histone modifiers for silencing of HOX 
genes68. 
 
Transcription 
lncRNAs can regulate gene transcription in several ways. One of these ways is acting 
as a co-regulator to enhance or repress gene expression. For example, the lncRNA Evf2, 
transcribed as a spliced anti-sense transcript from the Dlx5/6 enhancer, forms a complex 
with the TF DLX2 and MECP2 and regulates the activity of the Dlx5/6 enhancer by 
inhibiting DNA methylation levels (Figure 1)74,75. In addition, many lncRNAs are 
transcribed from active enhancers. These enhancer-associated lncRNAs have been 
found to be associated with enhanced levels of their neighboring protein-coding 
genes76. Another way is by forming a RNA-DNA triple helix to repress gene 
expression. For example, the DHFR gene contains two promoters, a general promoter 
and a minor promoter upstream of DHFR. The minor promoter transcribes a lncRNA 
that forms a RNA-DNA triple complex with the sequences of the major promoter and 
interferes with TFIIB to repress the expression of DHFR77. 
 
Splicing 
lncRNAs can also affect splicing, including alternative splicing. For example, the 
lncRNA MALAT1 regulates the concentration of splicing factors in nuclear speckle 
domains. It has been shown that MALAT1 can affect the concentration, distribution and 
activity of the serine/arginine splicing factor (Figure 1)78. Depletion of MALAT1 
changes the alternative splicing profile of multiple pre-mRNAs. Another example is 
the Zeb2 natural antisense transcript (NAT), which is upregulated after Snail1-induced 
epithelial mesenchymal transition. Zeb2 NAT is complementary to the 5’ splice site of 
an intron of the Zeb2 mRNA, a transcriptional repressor of E-cadherin. By masking this 
splice site, the translation machinery recognizes an internal ribosome entry site in the 
intron and retains it. This results in higher levels of the Zeb2 protein and consequently 
lower levels of E-cadherin mRNA and protein79. 
 
Translation 
lncRNAs can influence translation by acting directly on their target mRNAs and affect 
their stability. For example, the antisense transcript of BACE1 (BACE1-AS) is important 
for the stability of BACE1 mRNA, the precursor of an enzyme that processes the 
amyloid precursor protein into b-amyloid peptides involved in Alzheimer’s disease. 
The lncRNA BACE1-AS can form perfect base pairs with BACE1 mRNA to increase 
its stability. Moreover, the overlap between BACE1-AS and BACE1 includes a target 
site for miR-485-5p. This miRNA can also bind to BACE1 mRNA, but decreases the 
stability of BACE1 mRNA. Thus perfect base pairing of BACE1-AS with BACE1 
protects the mRNA from degradation by the miRNA (Figure 1)80. lncRNAs can also 
affect the NMD pathway. 1/2-sbsRNAs can bind to the 3’UTR of mRNA containing 
Alu elements. Imperfect base pairing forms binding sites for the RNA binding protein 
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STAU181. STAU1 can cause mRNA decay by binding to the NMD factor UPF1 and 
bringing it to the 3’UTR of the mRNA82. For example, one of the lncRNAs, 1/2-
sbsRNA1, binds to the 3’UTR of SERPINE1 and reduces the mRNA levels81. 
 
 
Figure 1. Models of lncRNA functions. lncRNAs can recruit chromatin remodeling complexes 
(Xist), regulate transcription (Evf2), influence pre-mRNA splicing (MALAT1) and regulate 
mRNA stability (BACE1-AS). SR: splicing regulator. 
 
1.2 GENETIC VARIATION 
New advances in sequencing and genotyping technologies have allowed scientists to 
look across the genome. These developments have identified millions of genetic 
variants in the human genome. Some of these genetic variants have been identified to 
be associated with human diseases and traits through genome wide association studies 
(GWAS). The challenge now is to unravel the mechanisms behind these associations. 
1.2.1 Single nucleotide polymorphisms 
Decoding the DNA sequence was one of the major scientific challenges of the last 
decades. The Human Genome Project published the first draft of the human genome in 
200130. However, genetic variation was not annotated in this version. Subsequent large-
scale projects, such as the 1000 Genomes Project83,84 and the International HapMap 
Consortium85,86, were initiated to identify and catalogue genetic variation. The most 
common genetic variation in humans are SNPs. A SNP is defined as a single nucleotide 
change that is present in at least 1% of the general population. In 2015, over 84 million 
validated SNPs have been identified in humans87. This number has now passed the 110 
million (dbSNP build 151). SNPs are distributed throughout the genome. SNPs located 
in protein-coding regions can be synonymous (do not alter the encoded amino acid 
sequence) or non-synonymous (do alter the encoded amino acid sequence) and can 
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induce changes or loss of protein function88,89. SNPs located in non-coding regions have 
the potential to be regulatory and can influence for example pre-mRNA splicing, TF 
binding and DNA methylation (discussed in more detail below)90-92. 
1.2.2 Genome wide association studies 
Using high-throughput genotyping technologies, GWAS have identified SNPs that are 
associated with many complex diseases. These studies look for SNPs with significant 
allele frequency differences between cases and controls. GWAS rely on the correlation 
structure of the genome, known as linkage disequilibrium (LD). Therefore, GWAS 
arrays contain only a few hundred thousand tag SNPs that represent SNPs in the same 
LD block. 
 
The first GWAS was published in 200293. A candidate locus on chromosome 6p21, 
including the lymphotoxin-a gene, was identified to be associated with myocardial 
infarction in a Japanese population. Many GWAS investigating different diseases 
followed. In 2005, a GWAS was published where SNPs in the CFH gene (encoding 
complement factor H) were identified to be associated with age-related macular 
degeneration94. DNA resequencing of this gene revealed a common coding variant that 
increases the risk for age-related macular degeneration. The first large GWAS, 
including 14,000 cases of seven common diseases (coronary heart disease, type 1 
diabetes (T1D), type 2 diabetes, rheumatoid arthritis (RA), Crohn’s disease, bipolar 
disorder, and hypertension) and 3,000 shared controls, was published by the Wellcome 
Trust Case Control Consortium in 200795. This study identified 24 independent 
association signals underlying these diseases. Since these studies, over 70,000 
associations have been published across many diseases and traits (NHGRI-EBI GWAS 
Catalog96,97). 
 
The primary goal of GWAS is to better understand complex diseases, however, the path 
from GWAS to biology is not straightforward. First, the effect of associated SNPs on 
disease risk is small. Second, the associated SNP is not necessarily the true causal SNP, 
it is likely to be in LD with the causal SNP. Fine mapping could pinpoint to the causal 
SNP. To fine map established GWAS loci, custom genotyping chips, such as the 
Immunochip98 (designed for studying immune related diseases) and Metabochip99 
(designed for studying metabolic, cardiovascular and anthropometric traits), have been 
developed. For example, the Immunochip contains around 195,000 SNPs from 186 
distinct associated loci from 12 immune related diseases. Third, the associated SNP 
does not tell which gene is implicated. Recent studies have shown that the gene can be 
located far from the associated SNP (even on different chromosomes)100,101. Fourth, the 
vast majority of disease-associated SNPs are located in non-coding regions and have 
the potential to be regulatory102-104. 
1.2.3 From genetic variation to function 
GWAS have identified thousands of disease-associated SNPs, but relatively little is 
known about the underlying mechanisms. Several consortia, including ENCODE33, 
FANTOM105, the NIH Roadmap Epigenomics Mapping Consortium106 and the 
Genotype-Tissue Expression (GTEx) project107, collected large amounts of data to help 
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improve the functional annotation of regulatory SNPs. This data includes information 
about gene expression, pre-mRNA splicing, protein expression, chromosomal 
conformation, chromatin accessibility, histone modifications, DNA methylation and 
TF binding. 
1.2.3.1 Expression quantitative trait loci 
Gene expression levels can be quantified easily for thousands of genes at once, for 
example by conducting RNA-seq. Genetic variants that affect gene expression levels 
are identified as expression quantitative trait loci (eQTLs). Several studies have shown 
an overrepresentation of eQTLs among GWAS loci108-110, suggesting that disease-
associated variants impact cellular phenotypes. Most of the observed eQTLs are located 
near the affected gene (usually within 1 megabase), known as local eQTLs (cis-eQTLs). 
Cis-eQTLs show widespread sharing across populations111 and are often located in 
regulatory elements, such as promoters and enhancers. In addition, lncRNA loci are 
enriched for cis-eQTLs110. 
 
There have been several studies that show that cis-eQTLs can aid in pinpointing the 
causal variant within a locus. For example, common SNPs in the FTO locus have been 
found to be associated with obesity in different populations112-114. Multiple studies have 
focused on unraveling potential mechanisms, however, mostly unsuccessful as there 
were no SNPs that disrupted the protein-coding sequence of FTO. A recent study 
discovered that the SNP rs1421085, located in the first intron of FTO, affects the 
expression of IRX3 and IRX5115. Functional studies suggested that IRX3 plays a role in 
obesity. However, for many other disease-associated variants the potential causal gene 
is still unknown as most of the common genetic variants are actually associated with 
one or more genes110,116. This implies that identifying the causal gene requires further 
investigation. In addition, the affected gene may be located several megabases away 
from the genetic variant, known as distal eQTLs (trans-eQTLs). 
 
The number of reported trans-eQTLs is much lower than the number of reported cis-
eQTLs. This is most likely a consequence of the small sample size of the initial eQTL 
mapping studies. However, trans-eQTL analyses can provide valuable insight into 
disease pathogenesis117-119. For example, a SNP in the IRF7 locus, associated with the 
autoimmune disease T1D, affects the expression of IRF7 in cis117. After viral exposure, 
it affects the expression of seven other genes in trans. This suggested a role of the IRF7-
driven inflammatory network in the etiology of T1D. A second example is the SNP 
rs4917014 in the IKZF1 locus, which is associated with the autoimmune disease 
systemic lupus erythematosus (SLE). This SNP affects the expression of IKZF1 in cis 
and the expression of five type I interferon-a (IFN-a) response genes and four genes 
involved in complement in trans119. These genes have increased binding of the TF 
encoded by IKZF1, suggesting the importance of IKZF1 in SLE. 
 
Genetic variants act via molecular pathways to alter phenotypes, which suggest that the 
effect of these variants will be specific to certain cell/tissue types relevant to the 
phenotype. Indeed, many studies have found that eQTLs can be cell type specific110,120-
122. This is especially true for trans-eQTLs, while 25.3% of cis-eQTLs were shared 
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across three or more tissues, only 3.8% of the trans-eQTLs were shared110. The trans-
eQTLs were mostly shared across a subset of related tissues, such as different brain 
regions110. However, eQTLs can be specific even across closely related cell types. In 
the above described obesity example, the SNP rs1421085 was found to affect the 
expression of IRX3 in pre-adipocytes but not in whole adipose tissue115. Therefore, this 
field is moving from heterogenous cell type samples, such as whole blood, to specific 
cell types, such as monocytes123 and regulatory T cells124. 
 
In addition to cell type specificity, eQTLs can be context specific. Some eQTLs might 
only be detectable under specific conditions, such as environmental stimuli. For 
example, a study in dendritic cells, assessing the effect of bacterial lipopolysaccharides 
(LPS), influenza and interferon-b (IFN-b) on gene expression, reported that about half 
of the observed eQTLs were only discovered in stimulated cells125. Similarly, a study 
in monocytes, mapping eQTLs before and after stimulation with bacterial LPS and 
interferon-g (IFN-g), detected that more than half of the cis-eQTLs were context 
specific123. They found that IFNB1, encoding the cytokine interferon B1, is among the 
cis-eQTLs in monocytes that is induced after 2 hours of LPS stimulation. However, 
after 24h of LPS stimulation, this cis-eQTL is no longer observed, but in turn multiple 
trans-eQTLs appear that are downstream targets of IFNB1. 
 
In addition to total gene expression (gene expression as an average over all alleles), 
allele-specific expression can be used to study eQTLs. Allele specific expression 
quantitative trait loci (aseQTLs) provide strong evidence of cis-regulatory mechanisms, 
whereas cis-eQTLs can arise from non-cis mechanisms126. 
 
Genetic variants can also be associated with alternative splicing, referred to as splicing 
quantitative trait loci (sQTLs). sQTLs tend to be enriched at 5’ and 3’ splice sites, but 
many SNPs located outside of these splice site regions have been associated with 
alternative splicing as well. These SNPs can for example modify regulatory RNA 
elements, such enhancers and silencers. Several studies have reported an enrichment of 
sQTLs among disease-associated variants127,128, suggesting that variants affecting 
alternative splicing could be the causal variants underlying GWAS signals. As an 
example, the SNP rs2248374, located close to a 5’ splice site of ERAP2, is associated 
with several diseases, including Crohn’s disease129. It deactivates the canonical 5’ splice 
site of ERAP2 and in turn activates a downstream splice site. This introduces a 
premature stop codon and the transcript is targeted by the NMD pathway for 
degradation90. Therefore, alternative splicing might be underlying some of the eQTLs. 
 
Besides eQTLs, protein quantitative trait loci (pQTLs) can be used to pinpoint potential 
causal variants from a GWAS130,131. pQTLs are often driven by regulation of mRNA 
levels, but some pQTLs may be involved in post-translational regulation132,133. 
1.2.3.2 Regulatory quantitative trait loci 
Epigenomic mechanisms, such as chromatin accessibility, histone modifications, DNA 
methylation and TF binding, can also underlie eQTLs. Genetic variants associated with 
chromatin accessibility, studied by mapping DNase I hypersensitivity sites, are called 
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DNase I sensitivity quantitative trait loci (dsQTLs). A study in lymphoblastoid cell 
lines found that 55% of the eQTLs are also dsQTLs134. In addition, they identified that 
dsQTLs are enriched within TF binding sites. A further study used histone 
modifications to detect differences in chromatin state associated with genetic variants, 
resulting in histone quantitative trait loci (hQTLs)135. Moreover, multiple studies have 
identified genetic variants that are associated with DNA methylation, known as 
methylation quantitative trait loci (mQTLs)136-138. Most of the mQTLs act in cis and 
mQTLs are enriched in TF and CTCF binding sites138. Taken together, dsQTLs, hQTLs 
and mQTLs mainly point to the disruption of TF binding sites as the mechanism driving 
the associations. 
 
In the above described obesity example, the SNP rs1421085, located in the first intron 
of FTO, was found to affect the expression of IRX3 and IRX5. The risk allele disrupts 
a motif for the repressor ARID5B, which leads to the derepression of an enhancer and 
increased expression of IRX3 and IRX5115. Similarly, the SNP rs968567, located within 
the promoter of FADS2, is associated with RA. The risk allele disrupts the binding of 
the TF SREBF2, which down-regulates the expression of FADS291. It is suggested that 
methylation of nearby CpG sites affect the binding of SREBF2139. These examples 
illustrate that integrating different molecular traits can uncover the pathways underlying 
GWAS hits. 
 
1.3 IMMUNITY 
Multicellular organisms have a sophisticated defense system to prevent and fight 
infections without harming the host. This system consists of two mechanisms: innate 
immunity, which is the initial mechanism against infections, and adaptive immunity, 
which is a more specialized and effective mechanism against infections. 
1.3.1 Innate immunity 
The innate immune system has several types of defensive barriers. The first barrier is 
the epithelial layer of the skin, gut and lungs, which physically interfere with the entry 
of pathogens. Pathogens do occasionally breach the epithelial barrier. When pathogens 
invade the tissue, it is up to the immune system to recognize and destroy them. The 
innate immune system recognizes particular structures that are shared by many 
pathogens but are absent in the host, known as pathogen-associated molecular patterns 
(PAMPs)140. The PAMPs are recognized by membrane-bound and cytoplasmic 
receptors in the host, such as Toll-like receptors (TLRs), C-type lectin receptors and 
nucleotide-binding oligomerization domain-like receptors141. They can also be 
recognized by circulating receptors, such as components of the complement system142. 
 
The tissue resident innate immune cells, such as macrophages, dendritic cells (DC) and 
in some cases mast cells, are among the first cells to encounter invading pathogens. 
These cells can get activated through the above-mentioned receptors and phagocyte the 
pathogen. This leads to the production of a variety of inflammatory mediators, such as 
cytokines (e.g. tumor necrosis factor a (TNF-a) and interleukin-1 (IL-1)) and 
chemokines (e.g. C-C motif chemokine ligand 2 (CCL2)). These inflammatory 
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mediators increase the permeability of the blood vessel, which facilitates the passage 
of recruited neutrophils and other leukocytes into the tissue to promote more 
inflammation140. 
 
Defense against viruses include special mechanisms that involve type I interferons 
(IFN-a and IFN-b) and natural killer (NK) cells. Although type I interferons can be 
produced by almost any cell type in the body, plasmacytoid DCs (pDCs) are specialized 
for the production of a large amount of type I interferons143. In addition, type I 
interferons are secreted by virus infected cells to induce cell-intrinsic antiviral states in 
infected cells and neighboring uninfected cells, which limit the spread of viral 
pathogens. Infected cells reduce the expression of major histocompatibility complex 
(MHC) class I on their cell surface, which stimulate NK cells to eliminate the infected 
cells by releasing cytotoxic granzymes and perforins144. Furthermore, type I interferons 
activate the adaptive immune system. 
1.3.2 Adaptive immunity 
The innate immune system stimulates the adaptive immune system to recruit more 
specialized components to eliminate the pathogen. Macrophages and DCs (and B cells), 
known as antigen presenting cells (APCs), display antigens (peptides) on MHC 
molecules to T cells. T cells recognize these complexes by their expressed T-cell 
receptor (TCR) and proliferate rapidly to produce a large number of cells with a certain 
specificity. B cells can recognize with their expressed B-cell receptor (BCR) a wide 
variety of antigens in their native form, including proteins, lipids and toxins, and can 
differentiate in response to an antigen into cells that secrete antibodies140. 
 
T-cell precursors are derived from hematopoietic stem cells in the bone marrow and 
migrate to the thymus for maturation into naïve CD4+ and CD8+ T cells. During T-cell 
maturation, TCRs undergo genetic recombination (V(D)J recombination) to increase 
their diversity. Each T cell expresses a single type of TCR that can bind to a specific 
peptide. Thereafter, naïve CD4+ and CD8+ T cells circulate to secondary lymphoid 
organs where they encounter APCs expressing MHC-peptide complexes. Naïve CD4+ 
T cells recognize MHC class II molecules present on APCs that display extracellular 
peptides, whereas naïve CD8+ T cells recognize MHC class I molecules present on all 
nucleated cells that display intracellular peptides140. However, cross-presentation has 
been demonstrated as well145. In addition, costimulatory molecules (CD80/CD86 on 
APCs and CD28 on T cells) are needed to fully activate the T cells146 (Figure 2). This 
results in clonal expansion of the T cells and differentiation into different T-cell subsets 
defined by the expression of specific master TFs and signature cytokines. Depending 
on the cytokine environment, CD4+ T cells can differentiate into T helper 1 (Th1) cells, 
Th2 cells, Th17 cells, T follicular helper (Tfh) cells and regulatory T cells. Th1 cells 
are primarily induced by IFN-g and IL-12 and secrete IFN-g promoted by the TF T-
bet147. In addition, IL-2 and TNF-a are produced as well. Th1 cells are crucial in the 
defense against intracellular viral and bacterial pathogens. Th2 cells are dependent on 
IL-2 and IL-4 for their differentiation147. The TF GATA3 promotes the expression of 
IL-4, IL-5 and IL-13, whereas it suppresses the expression of IFN-g148. Th2 cells play 
an important role in immune responses against large extracellular pathogens, such as 
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helminths. Th17 cells are developed from naïve CD4+ T cells in the presence of IL-6 
and IL-1b and are expanded in the presence of IL-23 and transforming growth factor 
beta (TGF-b). The TF RORgt promotes the expression of IL-17 and IL-22 that are 
secreted by Th17 cells147. These cells are important for immune responses towards 
specific fungi and extracellular bacteria. In addition to these Th cell subsets, Tfh cells 
are specialized providers of T cell help to B cells in the germinal center. Tfh cells are 
induced by IL-6 and IL-21, which promote the expression of the TF BCL6. In turn, 
BCL6 suppresses the expression of factors that mediate the differentiation of Th1, Th2 
and Th17 cells. Tfh cells primarily secrete IL-21 and IL-4149. Moreover, naïve CD4+ T 
cells can differentiate into regulatory T cells depending on TGF-b and IL-2. The master 
TF of regulatory T cells is FOXP3. Regulatory T cells have a crucial role in the 
maintenance of immunological tolerance to self and foreign antigens by for example 
secreting anti-inflammatory cytokines, such as IL-10 and TGF-b150. CD8+ T cells 
differentiate into cytotoxic T cells, which are involved in the destruction of infected 
cells expressing the antigen by the release of granzymes and perforins151. Some of the 
CD4+ and CD8+ develop into memory T cells, which will respond rapidly to repeated 
exposure of the same pathogen140. 
 
 
Figure 2. Interaction between an APC and T cell. Naïve CD4+ T cells recognize MHC class II 
molecules on APCs, whereas naïve CD8+ T cells recognize MHC class I molecules on APCs. 
 
B cells are produced in the bone marrow and are further matured in secondary lymphoid 
organs. Like TCRs, BCRs undergo V(D)J recombination to increase their diversity. B 
cells can recognize antigens directly (without MHC molecules) and can get activated 
under the influence of Th cells or other stimuli. This leads to clonal expansion of the B 
cell and differentiation into antibody-secreting plasma cells. BCRs of activated B cells 
can class switch its constant region to alter its effector function. In addition, BCRs of 
activated B cells can undergo a process known as somatic hypermutation to improve 
their ability to bind an antigen. Some activated B cells become long-lived B memory 
cells. Plasma cell secreted antibodies are involved in neutralizing pathogens and toxins, 
opsonizing and phagocytosis of pathogens and antibody-dependent cellular 
cytotoxicity140. 
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1.4 AUTOIMMUNITY 
One of the most important features of the adaptive immune system is to remain 
unresponsive to self-antigens, known as immune tolerance. It can be differentiated into 
central and peripheral tolerance. Central tolerance deletes, by apoptosis or anergy, high 
affinity autoreactive T cells before they develop into fully matured T cells152. 
Importantly, the TF AIRE controls the expression of self-antigens in the thymus that 
are usually only expressed in peripheral tissues153. However, some autoreactive T cells 
can escape thymus selection and mechanisms of peripheral tolerance will prevent their 
activation. For instance, regulatory T cells can inhibit the activation of potentially 
harmful naïve T cells and their differentiation into effector T cells154. 
 
The complex network that maintains immune tolerance can experience defects that lead 
to autoimmune diseases. Autoimmune diseases are characterized by unprovoked 
activation of the adaptive immune system, as well as the development of autoreactive 
T cells and/or autoantibodies, which leads to tissue injury. It is suggested that 
autoimmunity is a consequence of genetic and environmental factors and failed 
immune regulation155. Examples of autoimmune diseases are RA and idiopathic 
inflammatory myopathies. 
1.4.1 Rheumatoid arthritis 
RA is a chronic inflammatory disease that is characterized by inflammation and major 
damage of the synovium, which leads to joint swelling, bone destruction, pain and long-
term disability. The inflammation of the synovium is characterized by infiltrating cells 
dominated by CD4+ T cells and macrophages156,157. In addition, matrix-
metalloproteinases and pro-inflammatory cytokines contribute to the process of 
cartilage and bone destruction157. Furthermore, RA is characterized by circulating 
autoantibodies. The rheumatoid factor, an autoantibody to the Fc fragment of 
immunoglobulin G molecules, was first observed158. More recently, anti-citrullinated 
protein antibodies (ACPAs), antibodies directed against peptides and proteins that are 
citrullinated, were described in the serum of up to 70% of the RA patients159. 
Citrullination is a process where the amino acid arginine within the peptide sequence is 
replaced with citrulline by the enzyme peptidylarginine deiminase (PAD). Although 
the joint is the main target for inflammatory processes in RA, there are a number of 
extra-articular manifestations, including cardiovascular disease and interstitial lung 
disease (ILD)160. 
 
RA affects around 0.5 - 1% of the population in western countries and the incidence of 
RA increases with age. Like most other autoimmune diseases, women are more often 
affected than men (2.5-3.0/1)161. There is no cure for RA. Current treatment regimens 
aim at achieving clinical remission at an early stage of disease162. Therefore, it is crucial 
to diagnose patients early. To facilitate this, the American College of Rheumatology 
(ACR) and the European League Against Rheumatism (EULAR) designed 
classification criteria based on joint involvement, serology, acute-phase reactants and 
duration of symptoms163. 
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1.4.1.1 Risk factors 
The pathogenesis of RA is complex and implies several risk factors. The genetic 
component of RA was discovered from a number of twin studies. These studies show 
a concordance rate for RA of 12 - 15% for monozygotic twins compared to 2 - 5% for 
dizygotic twins and around 1% for the general population164-166. However, these studies 
implicate that many other factors, including environmental factors, are involved in the 
pathogenesis of RA. Epigenetics might have a role in the pathogenesis of RA as well. 
In addition, interactions between these factors can have a more significant impact on 
the overall risk of RA. 
 
Genetics 
Multiple specific genetic loci have been identified that are associated with RA. As for 
many other autoimmune diseases, the strongest genetic risk factor for RA is found in 
the human leukocyte antigen (HLA) locus, in particular the HLA-DRB1 gene. Over 100 
other genetic factors have also been associated with RA167. However, most of these loci 
have low effect sizes, with odds ratios typically less than 1.3, and our understanding of 
their role in the pathogenesis of RA is limited. One of the strongest associations, next 
to HLA-DRB1, is with SNPs in the PTPN22 locus. One of the recently found 
associations exist with SNPs in the PTPN2 locus168,169. 
 
HLA-DRB1 – The MHC class II gene HLA-DRB1 is the strongest genetic risk factor 
for RA and many other autoimmune diseases. HLA-DRB1 encodes the beta chain of 
the HLA-DR heterodimer (the alpha chain of the heterodimer is encoded by the MHC 
class II gene HLA-DRA). In addition to HLA-DR genes, the MHC class II locus on 
chromosome 6 is comprised of HLA-DP and HLA-DQ genes, encoding alpha and beta 
chains, which are also expressed as heterodimers on APCs. As mentioned above, these 
heterodimers on APCs present antigens (foreign and self) to CD4+ T cells, which 
become activated and stimulate B cells to produce antibodies. Multiple alleles of the 
HLA-DRB1 gene (HLA-DRB1*01, *04 and *10) have been found to be associated with 
RA, especially ACPA-positive RA. These so-called shared epitope (SE) alleles share 
sequences encoding five amino acids in position 70 - 74 of the third hypervariable 
region of the HLA-DR beta chain170. However, the SE region faces mainly away from 
the antigen-binding groove and the role of HLA-DRB1 SE alleles in antigen 
presentation was doubted. A more recent study found that amino acid 11 (or 13, as it is 
tightly linked to amino acid 11) of the antigen-binding groove of the HLA-DR beta 
chain was associated with ACPA-positive RA171. It has now been suggested that 
citrullinated peptides, bind to the positively charged peptide binding groove of the 
HLA-DR beta chain (mainly HLA-DRB1*04:01 and *04:04 alleles) and will be 
presented to CD4+ T cells172. 
 
The HLA-DRB1 SE alleles are not only related to RA susceptibility, they have been 
found to be associated with disease severity as well173-175. Patients with HLA-DRB1 SE 
alleles are more likely to develop joint damage and severe forms of RA compared to 
patients without HLA-DRB1 SE alleles. In addition, patients with double HLA-DRB1 
SE alleles are at an even higher risk of developing severe forms of RA175. 
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HLA-DRB1 SE alleles are associated with increased risk of ACPA-positive RA. A 
meta-analysis discovered that HLA-DRB1*13:01 alleles provide protection against 
ACPA-positive RA176. However, HLA-DRB1*13 alleles in combination with the HLA-
DRB1*03 alleles increase the risk of ACPA-negative RA177. 
 
Several interactions between HLA-DRB1 SE alleles and other RA risk loci have been 
identified, including PTPN22178,179 and MAP2K4180. For example, individuals carrying 
the HLA-DRB1 and PTPN22 risk allele were more susceptible to RA compared to 
individuals carrying one of these risk alleles178. Recently, an enrichment of interactions 
between HLA-DRB1 SE alleles and non-HLA risk SNPs was identified in ACPA-
positive RA179. 
 
PTPN22 – The gene PTPN22, encoding the phosphatase LYP, is a strong susceptibility 
gene that is shared by many autoimmune diseases, including T1D181,182, SLE182,183, 
polymyositis184 and RA182,185. The PTPN22 risk allele (rs2476601T), an amino acid 
substitution of arginine (R) to tryptophan (W) in codon 620 (R620W) of the non-
catalytic part of LYP, doubles the risk of developing ACPA-positive RA but not 
ACPA-negative RA186. Interestingly, the PTPN22 risk allele is not associated with 
multiple sclerosis (MS)182,187 and is protective in Crohn’s disease188. LYP is primarily 
expressed in lymphoid cells. In T cells, LYP has been identified as a negative regulator 
of TCR signaling by interacting with c-Cbl, CSK, VAV, Lck, Zap70, TCR zeta chain 
and Grb2189-192. However, the functional impact of LYP620W is still incompletely 
understood, as studies in T cells have described that LYP620W could be a gain-of-
function and a loss-of-function variant193,194. Moreover, some findings derived from 
mouse studies were not in line with the findings derived from human studies. For 
example, two studies showed that knock-in mice expressing the LYP variant homolog 
PEP619W had an increased TCR signaling and an expansion of effector-memory T 
cells195,196. There are also studies suggesting that LYP620W could influence the innate 
immune response by modifying TLR signaling197. 
 
PTPN2 – One of the recently identified candidate genes for RA is PTPN2. Several non-
coding SNPs in the PTPN2 locus have been reported to be associated with RA, juvenile 
idiopathic arthritis, inflammatory bowel disease and celiac disease95,198-203. The gene 
PTPN2 encodes a phosphatase from the same family as LYP. The expression of PTPN2 
was first identified in T cells, but PTPN2 is expressed in other lymphoid cells as well. 
PTPN2 is suggested to play a critical role in controlling immune reactions, as Ptpn2-
deficient mice die a few weeks after birth of systemic inflammation marked by 
excessive production of cytokines, including TNF and IFN-g, and nitric oxide204. 
However, the cell types that contribute to this phenotype remain widely unknown. 
PTPN2 has been found as an important negative regulator of cytokine signaling, 
including IL-2 and IFN-g signaling, by dephosphorylating JAK1, JAK3, STAT1, 
STAT3 and STAT5 molecules205-208. In addition, PTPN2 negatively regulates TCR 
signaling by dephosphorylating the Src family kinases Lck and Fyn209. Although many 
studies in mice and human have shown the importance of PTPN2 in autoimmunity, the 
exact mechanisms by which autoimmune disease-associated SNPs in the PTPN2 locus 
influence PTPN2 are not clear. 
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Environment 
Multiple environmental factors have been associated with RA. The most clearly 
demonstrated environmental risk factor is smoking. Tobacco smoking increases the risk 
of RA and the effect is dose dependent210-213. The association with smoking is only 
found in ACPA-positive RA211. In addition, a gene-environment interaction between 
smoking and HLA-DRB1 SE alleles has been reported for ACPA-positive RA214. 
Another study identified that smoking interacts with several non-HLA risk loci, 
including PTPN22 and PADI4215. In addition to smoking, other respiratory factors, such 
as exposure to silica dust, mineral oil and textile dust, are associated with an increased 
risk of developing ACPA-positive RA216-219. The association with textile dust was also 
observed for ACPA-negative RA219. Obesity has been associated with an increased risk 
of developing RA220-222, whereas alcohol consumption was found to be modestly 
associated with an reduced risk of developing RA223,224. Furthermore, periodontal 
disease is associated with an increased risk of developing RA225,226. The microbiota of 
the gut and lung might also play a role in the development of RA227,228. Virus infections 
such as Epstein-Barr virus have been associated with RA as well229. 
 
Epigenetics 
Epigenetic mechanisms, including DNA methylation and histone modifications, might 
be implicated in RA. A large number of loci have been identified to be differentially 
methylated in patients with RA compared to osteoarthritis patients or healthy 
individuals (mainly by studying fibroblast-like synoviocytes (FLSs))230-233. 
Interestingly, different DNA methylation patterns have been observed in FLSs from 
different joints of patients with RA234. In addition, DNA methylation might mediate 
gene-environment interactions in a cell type specific manner. For example, smokers 
with ACPA-positive RA carrying HLA-DRB1 SE alleles have higher DNA methylation 
levels than smokers with ACPA-positive RA who do not carry HLA-DRB1 SE 
alleles235. The difference in methylation was not observed in nonsmokers235. 
Furthermore, inhibitors of histone deacetylase have been described to have beneficial 
effects in mouse models of arthritis236,237, suggesting the importance of histone 
acetylation in RA. 
1.4.1.2 Disease mechanisms 
The initiation of RA is probably years before clinical symptoms can be observed. It is 
based on a combination of the above-mentioned risk factors. As most of the risk factors 
associate with ACPA-positive RA, it is suggested that ACPA-positive and ACPA-
negative RA are two different subtypes of RA. ACPA-positive RA development is 
determined by a characteristic genetic background (e.g. HLA-DRB1, PTPN22 and 
PADI4) upon which environmental factors operate to result in synovial inflammation. 
It is proposed that the environmental factors act in the epithelial layer of the skin, gut 
and lungs. For example, smoking induces the expression of PAD enzymes and 
citrullination in the lungs238. In addition, the bacterium P. gingivalis, which is common 
in periodontal disease, expresses PAD enzymes and can induce citrullination239. These 
factors can promote ACPA generation. Circulating ACPAs have been found to be 
present prior to RA onset (up to at least 10 years)240. However, the presence of ACPAs 
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is not sufficient to cause RA. The additional trigger that is required is still to be 
discovered. 
 
T cells play an important role in the pathogenesis of RA. The association of HLA-DRB1 
SE alleles with RA has pointed to the involvement of CD4+ T cells. Many other RA-
associated loci have important roles in T cells. In addition, it has been demonstrated 
that CD4+ T cells infiltrate the synovial membrane of inflamed joints. Furthermore, a 
therapy that prevents the interaction of the costimulatory molecules (abatacept) has 
beneficial effects in RA patients241,242. Moreover, CD4+ T cells were shown to be 
required for disease initiation in an antigen-induced arthritis model243. There is also 
evidence that differentiated CD4+ T cells play a role in the pathogenesis of RA. Th17 
cells are present in peripheral blood and synovial fluid of RA patients. These Th17 cells 
primarily secrete IL-17, which is suggested to promote bone erosion244. Regulatory T 
cells can also be detected in the inflamed joints of RA patients, however, it is suggested 
that the suppressive function of these cells is impaired by the inflammatory milieu245. 
The importance of regulatory T cells is also highlighted by the enrichment of RA risk 
loci with active H3K4me3 marks in regulatory T cells167,246. CD8+ T cells might play 
a role in RA as well, indicated by the association of MHC class I SNPs with 
susceptibility to RA171. Moreover, CD4+CD28null T cells with cytotoxic 
characteristics have been identified in a subset of RA patients247,248. 
1.4.2 Idiopathic inflammatory myopathies 
Idiopathic inflammatory myopathy, also known as myositis, is a rare (prevalence 
ranging from 8.7 to 25 per 100,000249-251) heterogeneous group of chronic inflammatory 
diseases that mainly affect the skeletal muscle. It leads to muscle weakness and is 
characterized by the presence of inflammatory cell infiltrates, including CD4+ and 
CD8+ T cells, in muscle tissue252,253. These T cells are predominantly of the CD28null 
phenotypes and might play a role in the destruction of muscle fibers by their cytotoxic 
properties254. Furthermore, myositis is also characterized by the presence of 
autoantibodies and the dysregulation of type I interferons. Moreover, other organs, such 
as the skin, joints, heart and lung can be involved as well255. Myositis is classified on 
the basis of distinct clinical and laboratory characteristics into subtypes, including the 
main subtypes dermatomyositis (DM), polymyositis (PM) and sporadic inclusion body 
myositis256-258. There is currently no cure for myositis, however, different treatments 
exist to slowdown disease progression, improve muscle function, and prevent damage 
of other organs. 
 
Myositis can be accompanied by the presence of autoantibodies. Up to 56% of the 
myositis patients have circulating autoantibodies259. These autoantibodies can be 
classified into myositis associated autoantibodies (MAAs) and myositis specific 
autoantibodies (MSAs). MAAs are present in other connective tissue diseases and 
target autoantigens such as Ro60/SSA, Ro52/TRIM21, PM-Scl, U1-RNP and Ku. 
MSAs are highly selective autoantibodies that, among many others, target the 
cytoplasmic enzymes aminoacyl-tRNA synthetases (ARSs), which catalyze the ATP-
dependent binding of an amino acid to its specific tRNA during protein synthesis260. 
Until now, antibodies against eight different ARSs have been identified and the most 
common one is anti-Jo-1. Up to 30% of the DM and PM patients have anti-Jo-1 
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antibodies259,261. These autoantibodies may be used as disease markers as they seem to 
correlate with distinct clinical features. For example, anti-Jo-1 antibodies are associated 
with ILD in myositis and correlate with disease activity262. 
 
Dysregulation of type I interferons is another characteristic of myositis. Expression 
levels of interferon regulated genes have been found to be substantially higher in 
muscle tissue of DM patients compared to patients with other types of myositis263. In 
addition to muscle tissue, interferon regulated genes have been found to be higher 
expressed in peripheral blood samples of patients with DM and PM and are correlated 
with disease activity264. 
 
The etiology of myositis is unknown, but many studies support the importance of 
genetic and environmental factors. HLA-DRB1*03:01 and HLA-B*08:01 alleles have 
been determined to be the strongest genetic risk factors for myositis184,265-267. However, 
different alleles might be associated with DM and PM184,267. In addition to the HLA 
alleles, PTPN22 is another strong genetic risk factor for PM184. Other suggestive 
myositis risk loci include BLK, CD28 and STAT4184. Environmental factors, such as 
exposure to ultraviolet light268, vitamin D deficiency269 and smoking270 have been found 
to be associated with myositis. An interaction between smoking and HLA-DRB1*03 is 
observed in anti-Jo-1 positive myositis patients270. It is suggested that this interaction 
may prime the development of anti-Jo-1 antibodies. 
1.4.2.1 Dermatomyositis 
DM typically presents as muscle weakness that is accompanied by skin rash. There is 
a higher prevalence among older individuals with a peak at 50 - 59 years of age and 
women are more often affected than men. DM may also be part of other syndromes, 
including anti-synthetase syndrome and myositis with overlap syndrome255. In addition, 
DM may be associated with cancer. It is reported that up to one third of the patients 
develop cancer within 5 years after DM diagnosis271. Regarding the inflammatory 
infiltrates in muscle biopsies of DM patients, they are located mainly in the perimysium 
and in perivascular areas and are predominated by CD4+ T cells with occasional pDCs 
and B cells252,253. 
1.4.2.2 Polymyositis 
PM patients show proximal symmetric weakness as DM patients but without skin rash. 
It is also more common in women than in men and is usually not seen in the 
childhood255. The cellular infiltrates are located mainly in the endomysium surrounding 
muscle fibers and typically dominated by CD8+ T cells252,253. Perforin in these CD8+ 
T cells is located towards the target muscle fiber272 and is suggested to contribute to the 
muscle cell damage only in PM patients273, indicating that different mechanisms in DM 
and PM are involved. 
1.4.3 Unmet needs in autoimmune diseases 
Autoimmune diseases are a significant clinical problem because of their chronic nature 
and the associated healthcare cost. Over the past decades, there have been major 
breakthroughs in understanding the mechanisms of RA and myositis, which resulted in 
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significant therapeutic advances to manage the symptoms of these disease. However, a 
clear understanding of the mechanisms that underlie RA and myositis is still lacking, 
which obstructs the development of remedies for these diseases. In addition, only a few 
molecular biomarkers have been identified to aid in stratifying RA and myositis patients 
for identifying the right therapeutics. 
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2 AIMS 
 
The autoimmune diseases RA and myositis are believed to arise from a combination of 
genetic and environmental factors. However, a clear understanding of the mechanisms 
that underlie these diseases is still lacking. The overall aim of the work presented in this 
thesis is therefore to better understand the functional role of genetic risk factors in the 
development of RA and myositis. 
 
The specific aims listed according to each paper are: 
 
I. To investigate the functional consequences of autoimmunity associated 
SNPs in the PTPN2 locus at chromosome 18. 
 
II. To determine the impact of the PTPN22 risk allele on CD4+ T-cell 
function in healthy individuals and RA patients. 
 
III. To find differentially expressed genes in healthy individuals with and 
without HLA-DRB1*04:01 alleles, the major genetic risk factor for RA. 
 
IV. To compare whole-genome transcriptomes of CD4+ and CD8+ T cells 
from peripheral blood between PM and DM. 
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3 EXPERIMENTAL PROCEDURES 
3.1 COHORTS AND METHODOLOGY 
In this work, different materials were used. In Paper I and II, data from the Swedish 
Epidemiological Investigation of Rheumatoid Arthritis (EIRA) study and the 
COMBINE study was used. In addition, different samples of healthy individuals and 
patients were collected. For each cohort, the cell sorting and RNA-seq methodology is 
briefly described. Detailed descriptions of the cohorts and methods can be found in the 
respective papers. 
3.1.1 EIRA study (Paper I) 
EIRA is a population-based case-control study. Incident cases of RA, from clinics in 
the middle and southern region of Sweden, were invited for the study from the year 
1996. All RA patients correspond to the 1987 ACR criteria274. To each RA patient, at 
least one healthy individual was randomly selected matched by age, sex and residence 
area. All participants were asked to fill out a comprehensive questionnaire about their 
lifestyle. All participants gave informed consent and the study was approved by the 
ethical review board at the Karolinska Institutet and the Stockholm regional ethical 
review board. 
 
DNA was extracted from whole blood samples by using a salting-out method and 
genotyped using the Illumina HumanHap300 Array. SNP imputation was done based 
on the 1,000 genomes project. DNA methylation levels were profiled using the Illumina 
HumanMethylation450 BeadChip275. In total, data of 335 healthy individuals and 354 
ACPA-positive RA patients was available. 
3.1.1.1 mQTLs 
Genotypes of 37 SNPs (autoimmune associated SNPs in high LD with these variants 
(r2 > 0.8)) and DNA methylation levels at 417 CpG sites (all CpG sites located in a 2 
Mb window around PTPN2) were extracted. Associations of these SNPs and CpG 
methylation levels were calculated using a linear regression model (GEM package). 
Sex, age and smoking status were included as covariates. 
3.1.2 COMBINE study (Paper I and II) 
The COMBINE study consists of a large collection of multi-omics data from RA 
patients. RA patients visiting the Karolinska University Hospital were included in the 
study and divided into three groups (all patients corresponded to the 1987 ACR or the 
2010 ACR/EULAR criteria). Group A includes early RA patients initiating 
methotrexate (MTX) treatment (naïve to treatment at baseline visit and after continuous 
treatment with MTX at follow-up visit (approximately three months later)). Group B 
includes RA patients initiating anti-TNF therapy (failed MTX treatment at baseline visit 
and after continuous treatment with anti-TNF at the follow-up visit). Group C includes 
RA patients initiating a second-line biologic treatment (failed anti-TNF therapy at 
baseline visit and after continuous treatment with second biologic at the follow-up 
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visit)276. In addition, healthy individuals, matched by age and sex, were recruited from 
the Uppsala Bioresource. All participants gave informed consent and the study was 
approved by the Stockholm and Uppsala regional ethics committees. 
 
DNA was extracted and genotyped using the Illumina OmniExpress array. SNP 
imputation was done based on the 1,000 genomes project. RNA was purified from 
peripheral blood mononuclear cell (PBMC) samples, prepared into sequencing libraries 
using the Illumina TruSeq RNA library prep kit and sequenced on the Illumina HiSeq 
2000. In Paper I, the raw reads were filtered based on quality and adapters were 
trimmed. The reads were aligned to the hg19 assembly using TopHat2277. Gene 
expression was quantified using HTSeq followed by TMM-normalization, mean-
scaling and log2 transformation (edgeR package)278. In Paper II, the reads were aligned 
to the hg38 assembly using STAR279. Expression values were determined using 
rpkmforgenes.py280. In total, data of 59 healthy individuals and 137 RA patients was 
available. 
3.1.2.1 eQTLs 
Genotypes of 41 SNPs (autoimmune associated SNPs in high LD with these variants 
(r2 > 0.8)) and expression levels of genes located in a 2 Mb window around PTPN2 
were extracted. Associations between SNPs and gene expression levels were calculated 
using a linear mixed model (nlme package). For healthy individuals, sex was used as a 
fixed effect and study individuals’ ID as a random effect. For RA patients, sex and 
patient groups (group A, B and C as described above) were used as fixed effects and 
study individuals’ ID as a random effect. 
3.1.3 Healthy individuals – HLA-DRB1 (Paper I and III) 
Blood samples from 32 healthy individuals (females between 55 and 73 years of age), 
selected by positivity for the HLA-DRB1 alleles *04, *13:01 and *15:01, were provided 
by the Uppsala Bioresource. All participants gave informed consent and the study was 
approved by the Uppsala regional ethics committee. 
 
The blood samples were processed by density gradient centrifugation using Ficoll to 
recover PBMCs. From the PBMCs, CD4+ T cells, CD8+ T cells, CD14+ monocytes 
and CD19+ B cells were isolated via positive selection using CD4, CD8, CD14 or 
CD19 Microbeads (Miltenyi) on the Miltenyi autoMACSâ Pro Separator. Total RNA 
was extracted from the PBMCs and the isolated cell subsets and RNA quantity/quality 
was assessed. Sequencing libraries were prepared for 90 samples using the Illumina 
TruSeq stranded total RNA library prep kit with Ribo-Zero and analyzed on an Illumina 
HiSeq 2500 sequencer. The raw reads were filtered based on quality and adapters were 
trimmed. Filtered reads were aligned to the hg38 assembly using STAR279 in two-pass 
mode with default settings. 
3.1.3.1 Mapping to the MHC region 
The hg38 assembly includes only one haplotype sequence for the MHC region (PGF, 
HLA-DRB1*15:01). Using the above-mentioned standard mapping method, many 
reads will misalign to the MHC region (chromosome 6: 28,500,000 – 33,500,000). 
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Therefore, reads were aligned to the eight available MHC reference haplotypes281. In 
short, unmapped reads and reads mapped to the MHC region (using the standard 
method) were extracted and realigned to the eight MHC reference haplotypes (Table 1) 
independently using STAR279 in two-pass mode. AltHapAlignR282 was used to estimate 
expression of genes in the MHC region using alignments to the eight available MHC 
reference haplotypes. Differentially expressed genes were identified using DESeq2283. 
The covariates age (< 65 and ³ 65), RIN value (groups) and RNA concentration 
(groups) were used. Differences in gene expression with Benjamini-Hochberg adjusted 
P-value < 0.05 and fold change (log2) > 1 were considered significant.  
 
Table 1. The eight available MHC reference haplotypes showing the MHC class II gene types. 
Haplotype HLA-DQA1 HLA-DQB1 HLA-DRB1 
PGF *010201 *0602 *150101 
COX *050101 *020101 *030101 
QBL *050101 *020101 *030101 
APD - - - 
DBB *0201 *030302 *070101 
MANN *0201 *0202 *070101 
MCF *0303 *030101 - 
SSTO *030101 *030501 *040301 
Dashes indicate the absence of a gene in the available reference haplotypes. 
3.1.4 Healthy individuals – PTPN22 (Paper I and II) 
Blood samples from 26 healthy individuals paired by age and sex, selected on PTPN22 
homozygous genotypes (risk genotype 1858TT and non-risk genotype 1858CC), were 
provided by the Uppsala Bioresource. All participants gave informed consent and the 
study was approved by the regional ethical review board in Uppsala. 
 
The blood samples were processed by density gradient centrifugation using Ficoll to 
recover PBMCs. PBMCs were labeled with LIVE/DEAD Near-IR Dead Cell dye 
(Invitrogen) and fluorescently labeled with anti-CD14, anti-CD4, anti-CD8, anti-CCR7 
and anti-CD45RA to sort naïve CD4+ T cells (CD45RA+CCR7+) using an influx sorter 
(BD). The naïve CD4+ T cells were activated with anti-CD3/CD28 beads (Dynabeads) 
for 16 h. Total RNA was extracted of naïve CD4+ T cells before and after activation 
and RNA quantity/quality was assessed. Sequencing libraries were prepared for 32 
samples using the Illumina TruSeq stranded mRNA kit and analyzed on an Illumina 
HiSeq 2500 sequencer. The reads were aligned to the hg38 assembly using STAR279 
with default settings. Expression values were determined using rpkmforgenes.py280. 
Genes were tested for differential expression using the Mann-Whitney U test. 
Differences in gene expression with P-value < 0.05 and fold change (log2) > 1.2 were 
considered significant. 
3.1.5 Myositis patients (Paper IV) 
Blood samples from 33 myositis patients (treated with different therapies) visiting the 
Karolinska University Hospital were selected for the study on basis of diagnosis (PM 
and DM) and HLA-DRB1*03 status (positive and negative). All patients gave informed 
consent and the study was approved by the Stockholm regional ethics board. 
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The blood samples were processed by density gradient centrifugation using Ficoll to 
recover PBMCs. From the PBMCs, CD4+ T cells, CD8+ T cells, CD14+ monocytes 
and CD19+ B cells were isolated via positive selection using CD4, CD8, CD14 or 
CD19 Microbeads (Miltenyi) on the Miltenyi autoMACSâ Pro Separator. Total RNA 
was extracted from the isolated cell subsets and RNA quantity/quality was assessed. 
Sequencing libraries were prepared for 24 samples using the Illumina TruSeq stranded 
total RNA library prep kit with Ribo-Zero and analyzed on an Illumina HiSeq 2500 
sequencer. The raw reads were filtered based on quality and adapters were trimmed. 
Filtered reads were aligned to the hg38 assembly using STAR279 with default settings. 
Differentially expressed genes were identified using DESeq2283. The covariates sex, 
age (< 60 and ³ 60), RIN value and HLA-DRB1*03 status (or diagnosis for HLA-
DRB1*03-positive versus HLA-DRB1*03-negative) were used. Differences in gene 
expression with Benjamini-Hochberg adjusted P-value < 0.05 were considered 
significant. 
 
3.2 ADDITIONAL METHODS 
In addition to the above-mentioned methods for each specific cohort, more general 
methods were used, which are briefly described in this section. Detailed descriptions of 
these methods can be found in the respective papers. 
3.2.1 Knockdown of LINC01882 (Paper I) 
Jurkat T cells (LGC Standards) were kept in RPMI-1640 medium supplemented with 
10% fetal bovine serum, L-glutamine and penicillin/streptomycin in a 37°C incubator 
with 5% CO2. Jurkat T cells were transfected with a mixture of a dsiRNA (50nM; 
Integrated DNA Technologies) and an antisense LNAÔ GapmeR (50nM; Exiqon) 
targeting the second exon of LINC01882 using Lipofectamine 2000 according to the 
manufacturer’s protocol. In addition, a mixture of the dsiRNA NC1 (50nM; Integrated 
DNA Technologies) and an antisense LNAÔ GapmeR (50nM; Exiqon) was used as 
negative control. Cells were harvested 24 and 48 hours after transfection. Total RNA 
was extracted and RNA quantity/quality was assessed. Sequencing libraries were 
prepared for eight samples using the Illumina TruSeq stranded total RNA library prep 
kit with Ribo-Zero and analyzed on an Illumina HiSeq 2500 sequencer. The raw reads 
were filtered based on quality and adapters were trimmed. Filtered reads were aligned 
to the hg38 assembly using STAR279 with default settings (for lncRNAs, the FANTOM 
CAT assembly was used64). Differentially expressed genes, adjusted for time point and 
experiment, were identified using DESeq2283. Differences in gene expression with 
Benjamini-Hochberg adjusted P-value < 0.05 were considered significant. 
3.2.2 Quantitative real-time PCR (Paper I and II) 
Efficiency of LINC01882 knockdown in Jurkat T cells was evaluated by quantitative 
real-time PCR using iQÔ SYBRÒ Green Supermix (Bio-Rad laboratories) on a Bio-
Rad CFX384 Real-Time PCR system. SFRS9 and HPRT were used to normalize gene 
expression levels. In addition, CFLAR and TNFRSF9 expression levels were measured 
by quantitative real-time PCR using SsoAdvancedÔ Universal SYBRÒ Green 
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Supermix (Bio-Rad laboratories) on a Bio-Rad CFX384 Real-Time PCR system. 
GAPDH and B2M were used to normalize gene expression levels. Data of all 
experiments was analyzed using the comparative CT method284. 
3.2.3 HLA typing (Paper III and IV) 
HLA typing was performed using sequence-specific primers from the HLA-DR low-
resolution kit (Olerup SSP) and analyzed by agarose gel electrophoresis285. In addition, 
HLA-DR4 subtyping was performed for HLA-DRB1*04 positive individuals. An 
interpretation table was used according to the manufacturer’s instructions to determine 
the specific genotype of each sample. Moreover, seq2HLA286 was used to impute 
classical HLA alleles from RNA-seq data. 

  29 
4 RESULTS AND DISCUSSION 
4.1 PAPER I: T CELLS ARE INFLUENCED BY A LONG NON-
CODING RNA IN THE AUTOIMMUNE ASSOCIATED PTPN2 
LOCUS 
4.1.1 Rationale 
Previous GWAS have shown that several non-coding SNPs in the PTPN2 region are 
associated with different autoimmune diseases, including RA. The Wellcome Trust 
Case Control Consortium reported an association of the intergenic SNP rs2542151 with 
Crohn’s disease, T1D and RA287. Later studies identified a stronger association for the 
intronic SNP rs1893217 with Crohn’s disease and T1D198,288. In addition, the intronic 
SNPs rs2847297, rs62097857 and rs8083786 were reported to be associated with 
RA167,168,289. PTPN2 has been identified to be an important factor in autoimmunity, as 
it functions as a negative regulator of TCR and cytokine signaling209. However, the 
functional mechanisms by which autoimmune disease-associated SNPs in the PTPN2 
locus influence PTPN2 are not clear. We therefore set out to investigate the link 
between non-coding SNPs in the PTPN2 region and autoimmunity. 
4.1.2 QTL analyses in healthy individuals and RA patients 
To determine the link between risk variants in the PTPN2 locus and autoimmunity, 
mQTL and eQTL analyses were performed. mQTL analyses were performed based on 
DNA methylation data of the EIRA study. In healthy individuals as well as RA patients, 
a strong association was detected for rs1893217 (and SNPs in high LD with rs1893217) 
and DNA methylation levels at four CpG sites in a CpG island 7.5 kb downstream of 
PTPN2. Interestingly, three lncRNAs (RP11-973H7.1, RP11-973H7.5 and 
LINC01882) are located downstream of this CpG island (within 30 kb). We therefore 
tested for associations between risk variants in the PTPN2 locus and expression levels 
of PTPN2 and the lncRNAs RP11-973H7.1 and LINC01882 (RP11-973H7.5 could not 
be detected). Using GTEx data and COMBINE data, no significant associations were 
found for risk variants in the PTPN2 locus and PTPN2 expression levels in whole blood 
and PBMC samples of healthy individuals and RA patients. However, a recent study 
showed that the rs1893217 risk allele is associated with decreased levels of PTPN2 in 
CD4+CD45RO+ T cells of healthy individuals207. This discrepancy might be due to the 
materials (whole blood and PBMCs) we used, as the majority of eQTLs are usually cell 
type specific. On the other hand, we identified significant associations between risk 
variants in the PTPN2 locus and expression levels of the lncRNAs RP11-973H7.1 and 
LINC01882 in whole blood and PBMC samples of healthy individuals and RA patients. 
 
SNPs in high LD with rs12971201 are most significantly associated with the expression 
of RP11-973H7.1 in healthy individuals and RA patients. Different SNPs are most 
significantly associated with the expression of LINC01882 in healthy individuals and 
RA patients. The SNP rs11875687 is most significantly associated with the expression 
of LINC01882 in healthy individuals, whereas the SNPs in high LD with rs12971201 
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are most significantly associated with the expression of LINC01882 in RA patients. 
Although different SNPs are associated with the expression of LINC01882 in healthy 
individuals and RA patients, LINC01882 is not differentially expressed between 
healthy individuals and RA patients. In addition, the expression levels of RP11-
973H7.1 were also not different between healthy individuals and RA patients. This 
might reflect that the expression of these lncRNAs are only important in a specific cell 
type and that the differences in expression might therefore not be identified in PBMC 
samples. In addition, we measured expression levels in patients with chronic RA, where 
the differences in lncRNA expression might have already been normalized by other 
pathways. 
 
The mQTLs and eQTLs are inversely correlated, which is in line with the traditional 
view that decreased DNA methylation levels are associated with increased gene 
expression levels. However, it is not clear from our data whether the change in 
expression of RP11-973H7.1 and LINC01882 is a direct consequence of DNA 
methylation changes or that other factors are involved. The data sources HaploReg290 
and RegulomeDB291 provided evidence that the SNPs rs2852151 and rs3826557, in 
high LD with rs12971201, might affect the binding sites for TFs and DNA-damage 
repair proteins, such as RAD21, CTCF, STAT3, FOS and STAT1. Further studies are 
needed to identify if these proteins are involved in the regulation of RP11-973H7.1 and 
LINC01882 expression. Moreover, there is data showing that the promoter region of 
PTPN2, where the SNP rs4797709 (in high LD with rs12971201) is located, physically 
interacts with LINC01882 in different cell types292. 
 
 
              
Figure 3. Genotype effect on methylation and expression level in healthy individuals. A) 
Association between rs12971201 genotype and methylation levels at the CpG site cg23598886 in 
whole blood of healthy individuals. B) Association between rs12971201 genotype and expression 
levels of LINC01882 in PBMCs of healthy individuals. 
4.1.3 Expression profile of the lncRNAs in T cells 
The mQTL and eQTL analyses pointed to the involvement of the lncRNAs RP11-
973H7.1 and LINC01882 in different autoimmune diseases, however, the function of 
A                     B 
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these lncRNAs is not known. We determined the cell types in which RP11-973H7.1 
and LINC01882 are expressed. The lncRNAs were detected in CD4+ T cells and CD8+ 
T cells, but not in CD14+ monocytes and CD19+ B cells. In addition, a H3K27ac peak 
just upstream of the lncRNA RP11-973H7.1 was only identified in different T cell 
subsets in ChIP-seq data from the Roadmap Epigenomics project. This shows that 
RP11-973H7.1 and LINC01882 are only expressed in different subsets of T cells. 
Furthermore, we identified that expression of LINC01882 upon CD3/CD28 stimulation 
was decreased in naïve CD4+ T cells. Although we identified that the lncRNAs are 
expressed in T cells, the expression levels are low. 
4.1.4 Knockdown of LINC01882 in Jurkat T cells 
To identify potential functions of LINC01882, we silenced the expression of this 
lncRNA in Jurkat T cells using a combination of an antisense oligonucleotide and RNA 
interference. Silencing of LINC01882 did not influence the expression levels of PTPN2. 
To identify potential other targets, we performed RNA-seq on these samples. Silencing 
of LINC01882 modestly changed the expression of 12 genes, six genes were 
upregulated and six genes were downregulated. The most upregulated gene upon 
LINC01882 knockdown is BZRAP1, however, the function of BZRAP1 in immune 
cells is not known. One of the downregulated genes upon LINC01882 is ZEB1, 
encoding a TF that represses the levels of IL-2 when it cooperates with CtBP2293. 
However, it is not predicted that LINC01882 binds directly to ZEB1. It was recently 
shown that miR-200a-3p negatively regulates the recruitment of ZEB1 and CtBP2 to 
the promoter of IL-2, which promotes the production of IL-2 in T cells294. It is predicted 
that miR-200a-3p and LINC01882 can interact. We therefore hypothesize that 
LINC01882 regulates the expression of ZEB1 by regulating the levels of miR-200a-3p. 
Moreover, it is predicted that miR-200a-3p can interact with KLF12 and MAP2K4, 
which are both affected by the silencing of LINC01882. These results suggest that 
LINC01882 is potentially involved in the regulation of IL-2 (Figure 4). As mentioned 
above, IL-2 plays a crucial role in the maintenance of regulatory T cells and 
dysregulation may lead to the development of autoimmune diseases, including RA. 
 
 
Figure 4. Hypothetical role of LINC01882. SNPs in the PTPN2 locus are associated with the 
expression of LINC01882. Silencing of LINC01882 decreases the expression of ZEB1, KLF12 
and MAP2K4, which might be mediated via the miRNA miR-200a-3p. The protein of ZEB1 
represses the expression of IL-2, which is involved in T-cell activation. Blue indicates changes in 
expression of genes supported by our data, while red indicates suggestive changes. 
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4.1.5 Concluding remarks 
We show that autoimmune disease-associated SNPs in the PTPN2 locus are associated 
with the expression of several lncRNAs, including LINC01882. We identified that 
LINC01882 might play a role in T-cell activation by regulating IL-2 levels. Overall, 
this suggests that LINC01882 can be linked to several autoimmune diseases, including 
RA. 
 
4.2 PAPER II: EOMES-POSITIVE CD4+ T CELLS ARE 
INCREASED IN PTPN22 (1858T) RISK ALLELE CARRIERS 
4.2.1 Rationale 
One of the strongest susceptibility genes for many autoimmune diseases, including RA, 
is PTPN22181-185. The PTPN22 risk allele (rs2476601; 1858T) substitutes an arginine 
(R) to tryptophan (W) in codon 620 (R620W) of the non-catalytic part of LYP (encoded 
by PTPN22). LYP has been identified as a negative regulator of TCR signaling. 
However, the functional impact of LYP620W is still controversial. Studies in T cells 
have described that LYP620W could be a gain-of-function variant193, leading to 
decreased TCR signaling, or a loss-of-function variant194, leading to increased TCR 
signaling. In addition, knock-in mice expressing the LYP variant homolog PEP619W 
had increased TCR signaling and expansion of effector-memory T cells195,196. We 
therefore set out to study the functional consequences of the PTPN22 risk allele on 
CD4+ T-cell function in healthy individuals and RA patients. 
4.2.2 Differential expression in naïve CD4+ T cells 
As LYP is primarily expressed in T cells189, we first evaluated if the PTPN22 risk 
genotype affects the frequency of CD4+ Th cell subsets in healthy individuals. The 
frequencies of Th1 (CXCR3+), Th17 (CCR6+), Th1Th17 (CXCR3+CCR6+) and Tfh 
(CXCR5+) cell subsets were not different between healthy individuals carrying 
1858CC and 1858TT. In addition, there were no differences observed in the frequencies 
of total regulatory CD4+ T cells, resting regulatory T cells (CD45RA+FOXP3low) and 
activated regulatory T cells (CD45RA-FOXP3high) between healthy individuals 
carrying 1858CC and 1858TT. A trend was observed towards an increase of the non-
regulatory T cell fraction (CD45RA-FOXP3low) in 1858TT carriers. 
 
Although no significant differences were observed in the frequency of the T-cell subsets 
between 1858CC and 1858TT carriers, it is possible that the small differences that were 
observed could affect our further analyses. We therefore isolated a homogenous 
population of naïve CD4+ T cells (CD45RA+CCR7+) from healthy individuals 
carrying 1858CC and 1858TT. TCR activation of the isolated naïve CD4+ T cells 
modified the expression of a large number of genes, however, most of these genes were 
not differentially expressed between 1858CC and 1858TT carriers. This shows that the 
presence of the risk allele does not induce a global change of TCR-regulated genes in 
naïve CD4+ T cells. This was further confirmed by no observed differences in calcium 
flux in CD4+ T cells from healthy individuals carrying the 1858CC and 1858TT 
genotype. 
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PTPN22 was not differentially expressed between 1858CC and 1858TT carriers before 
and after TCR activation. However, 57 genes were differentially expressed between 
1858CC and 1858TT carriers after TCR activation. Among these genes, 20 genes were 
higher expressed in healthy individuals carrying 1858CC and 37 genes were higher 
expressed in healthy individuals carrying 1858TT. The genes higher expressed in 
1858TT carriers were enriched with genes belonging to the Gene Ontology terms295 
ribosome and apoptosis. It has been shown that TCR stimulation increases the 
expression of ribosomal proteins296. Higher levels of ribosomal protein genes might 
suggest that PTPN22 risk allele carriers have increased cell proliferation. This is further 
supported by higher expression levels of CFLAR and TNFRSF9 in 1858TT carriers 
(Figure 5). These results were confirmed by quantitative real-time PCR. CFLAR 
encodes the protein FLIP, which suppresses apoptosis by forming heterodimers with 
pro-caspase 8 to inhibit its activation297. It has been shown that FLIP-deficient T cells 
have defective survival upon TCR stimulation298. In addition, high levels of FLIP have 
been found in cytotoxic CD4+CD28null T cells299,300. TNFRSF9 encodes the protein 4-
1BB (CD137), which is a co-stimulatory molecule transiently expressed after TCR 
stimulation301. We identified that the expression of 4-1BB on the surface of CD4+ T 
cells stimulated with staphylococcal enterotoxin B for four days was increased in ten 
out of twelve individuals carrying the PTPN22 risk genotype. Co-stimulation through 
4-1BB induces the expression of the TF EOMES302,303, which drives cytotoxic 
differentiation. Since the expression of EOMES was not induced in naïve CD4+ T cells 
after TCR activation, we did not observe differential expression of EOMES in naïve 
CD4+ T cells of healthy individuals carrying 1858CC versus 1858TT. However, higher 
expression levels of EOMES were observed in PBMCs of healthy individuals carrying 
1858CT versus 1858CC from the COMBINE study (Figure 6A). Moreover, CFLAR 
and TNFRSF9 have been found to be associated with RA167. Overall, this suggests that 
CD4+ T cells of healthy individuals carrying the PTPN22 risk allele are more resistant 
to apoptosis and more prone to differentiate into cytotoxic T cells. 
 
 
              
Figure 5. Differential expression of CFLAR and TNFRSF9 in TCR stimulated naïve CD4+ T 
cells of healthy individuals carrying the PTPN22 risk genotype (TT) and non-risk genotype (CC). 
A) Differential expression of CFLAR in 1858CC and 1858TT carriers. B) Differential expression 
of TNFRSF9 in 1858CC and 1858TT carriers. 
A                     B 
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4.2.3 EOMES+CD4+ T cells in healthy individuals and RA patients 
These results led us to examine the frequency of EOMES+CD4+ T cells in PBMCs of 
healthy individuals carrying 1858CC and 1858TT. We found that the frequency of 
EOMES+CD4+ T cells was increased in healthy individuals carrying the PTPN22 risk 
genotype (Figure 6B). As the expression of EOMES in naïve CD4+ T cells is virtually 
absent304, the increased expression of EOMES in CD4+ T cells could be due to a 
skewed frequency of naïve CD4+ T cells in healthy individuals carrying 1858TT. We 
indeed found that nine out of thirteen healthy individuals carrying 1858TT presented a 
decreased frequency of naïve CD4+ T cells. The frequency of EOMES tended to be 
increased in memory CD4+ T cells (CCR7-CD45RA-) of healthy individuals carrying 
1858TT. However, the frequency of EOMES was not affected in the different memory 
CD4+ T-cell subsets, including central memory (CCR7+CD45RA-), effector memory 
(CCR7-CD45RA-) and terminally differentiated effector memory (CCR7-CD45RA+) 
cells. Thus we showed that healthy individuals carrying the PTPN22 risk genotype have 
a higher frequency of EOMES+CD4+ T cells, which is correlated with a decreased 
frequency of naïve CD4+ T cells. 
 
 
              
Figure 6. RNA and protein levels of EOMES in healthy individuals carrying the PTPN22 risk 
allele (1858T) A) Differential expression of EOMES in PBMCs of 1858CC and 1858CT carriers. 
B) Frequency of EOMES+CD4+ T cells in 1858CC and 1858TT carriers. 
 
We then investigated the relevance of EOMES+CD4+ T cells in RA patients. We 
collected paired samples of peripheral blood and synovial fluid from twelve RA 
patients with different PTPN22 genotypes. We found that the frequency of 
EOMES+CD4+ T cells was significantly higher in synovial fluid compared to 
peripheral blood, as all CD4+ T cells are of memory phenotype in synovial fluid. 
However, the frequency of EOMES+CD4+ T cells was not different in synovial fluid 
of RA patients carrying the different PTPN22 genotypes. This might suggest that other 
factors in the synovial fluid of RA patients can contribute to their differentiation. 
Moreover, differences in treatment and inflammatory processes between the RA 
patients might contribute to mask part of the effect of the risk allele in RA patients. 
Furthermore, EOMES has been shown to regulate the levels of perforin 1305,306. We 
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found an increased frequency of perforin 1 in EOMES+CD4+ T cells compared to 
EOMES-CD4+ T cells, with higher frequencies observed in RA patients carrying the 
PTPN22 risk allele. In addition, perforin 1 expression is correlated with granzyme A 
expression and to a lesser extent with granzyme B expression. Notably, granzyme B 
expression was restricted to EOMES+CD4+ T cells while granzyme A expression 
could be found to some extent in EOMES-CD4+ T cells. Moreover, levels of perforin 
1 are higher in ACPA-positive RA patients carrying the PTPN22 risk allele. The same 
results were observed in EOMES+CD8+ T cells of synovial fluid from RA patients, 
however, perforin 1 expression was not different between PTPN22 risk and non-risk 
alleles. 
 
Although this data demonstrates a link between PTPN22 risk alleles and the generation 
of CD4+ T cells with cytotoxic characteristics, the exact mechanisms driving the 
generation of EOMES+CD4+ T cells in RA and other autoimmune diseases is currently 
unknown. It has been shown that the expression of soluble 4-1BB and 4-1BBL is 
increased in RA patients307, which might contribute to the induction of EOMES. In 
addition, pro-inflammatory cytokines such as IL-15 could participate in driving the 
accumulation of cytotoxic CD4+ T cells in synovial tissue of RA patients308,309. 
4.2.4 Concluding remarks 
We identified that the frequency of EOMES+CD4+ T cells is increased in healthy 
individuals carrying the PTPN22 1858TT risk genotype compared to healthy 
individuals carrying the PTPN22 1858CC non-risk genotype. Overall, this suggests a 
new role for the PTPN22 risk genotype in the context of RA through the generation of 
CD4+ T cells with cytotoxic characteristics. 
 
4.3 PAPER III: RNA EXPRESSION OF HLA-DRB AND HLA-DQ 
GENES IN HEALTHY INDIVIDUALS DIFFERS BETWEEN 
MHC CLASS II HAPLOTYPES 
4.3.1 Rationale 
The MHC class II gene HLA-DRB1 is the major genetic susceptibility locus for RA and 
many other autoimmune diseases. HLA-DRB1 SE alleles have been associated to 
ACPA-positive RA171 and are proposed to reflect a favored binding of citrullinated 
peptides to the binding groove of the HLA-DR beta chain172. However, other 
mechanisms such as differential gene expression linked to certain HLA-DRB1 alleles 
have not been thoroughly investigated. We therefore studied genome-wide gene 
expression profiles in PBMCs, CD4+ T cells, CD8+ T cells and CD14+ monocytes of 
healthy individuals with HLA-DRB1 SE-positive (*04) and SE-negative (*13:01 or 
*15:01) alleles. HLA-DRB1*13:01 alleles provide protection against ACPA-positive 
RA176, while HLA-DRB1*15:01 alleles are not associated with RA but confer the 
strongest risk for developing other autoimmune diseases, including MS310. 
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4.3.2 Differential expression in PBMCs 
We first focused on identifying differentially expressed genes in PBMCs of healthy 
individuals carrying HLA-DRB1 SE-positive versus SE-negative alleles. We identified 
no differentially expressed non-MHC genes between HLA-DRB1 SE-positive and SE-
negative individuals (adjusted P-value < 0.05 and fold change (log2) > 1). It might be 
possible that cell type specific differences in gene expression were missed due to the 
heterogenous mixture of cell types in the PBMC samples. 
 
Using the eight MHC reference haplotypes for mapping reads to the MHC region 
(described above), we identified five MHC class II genes that were differentially 
expressed between HLA-DRB1 SE-positive and SE-negative individuals. We found 
that HLA-DRB4, HLA-DQA2, HLA-DRB1 and HLA-DQA1 had higher expression 
levels in HLA-DRB1 SE-positive individuals, whereas HLA-DQB1 had higher 
expression levels in HLA-DRB1 SE-negative individuals. The differential expression 
of HLA-DRB4 between HLA-DRB1 SE-positive and SE-negative individuals is 
expected as we compare a group that has HLA-DRB4 (individuals carrying HLA-
DRB1*04) with a group that does not have HLA-DRB4 (individuals carrying HLA-
DRB1*13 and *15 (Figure 7)). Interestingly, the expression of HLA-DRB1 was also 
different between HLA-DRB1 SE-positive and SE-negative individuals, although HLA-
DRB1 is present in all groups (individuals carrying HLA-DRB1*04, *13 and *15 
(Figure 7)). In addition to HLA-DRB1, the expression of HLA-DQA1, HLA-DQA2 and 
HLA-DQB1 was different between HLA-DRB1 SE-positive and SE-negative 
individuals, which is consistent with the extended HLA-DR/HLA-DQ haplotype. 
 
 
Figure 7. Gene map of the MHC region. The MHC region on the short arm of chromosome 6 
contains MHC class I, II and III. MHC class II genes include HLA-DR, HLA-DQ and HLA-DP. 
The different HLA-DR haplotypes (HLA-DRB1*04, *13 and *15) are linked with only one of the 
following genes: HLA-DRB4, HLA-DRB3 or HLA-DRB5. 
 
Although this strategy mapped the reads more accurately282, there are several issues that 
remain and may interfere with gene expression profiling in the MHC locus. First, the 
amount of available MHC reference haplotypes is limited281. There are only references 
available for the haplotypes with HLA-DRB1*03:01, *04:03, *07:01 and *15:01 alleles 
(Table 1). As there is no MHC reference haplotype containing HLA-DRB1*13:01, we 
had to remove all individuals carrying HLA-DRB1*13:01 from our analysis. Second, 
the HLA-DRB1*04:01 samples are mapping to the best matched MHC reference 
haplotype SSTO (HLA-DRB1*04:03), which could potentially lower the number of 
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mapped reads. Moreover, the efficiency of read mapping can be different for different 
haplotypes. We therefore performed our differential expression analyses on samples 
with only HLA-DRB1*03:01 as second allele. 
 
Taken these issues into account, we identified three MHC class II genes that were 
differentially expressed between individuals carrying HLA-DRB1*03:01/*04:01 and 
*03:01/*15:01. As expected, HLA-DRB4 was higher expressed in HLA-
DRB1*03:01/*04:01 individuals and HLA-DRB5 was higher expressed in HLA-
DRB1*03:01/*15:01 individuals. In addition, HLA-DQB1 was higher expressed in 
HLA-DRB1*03:01/*15:01 individuals compared to HLA-DRB1*03:01/*04:01 
individuals. Although HLA-DRB1 was higher expressed in individuals carrying HLA-
DRB1*03:01/*04:01 compared to HLA-DRB1*03:01/*15:01, it did not reach statistical 
significance due to the small sample size. These results show that HLA-DRB and HLA-
DQ genes are differentially expressed in PBMCs of HLA-DRB1*03:01/*04:01 versus 
*03:01/*15:01 healthy individuals. 
4.3.3 Differential expression in isolated cell subsets 
To identify whether these observed differences were cell type specific, we performed 
differential expression analyses on isolated CD4+ T cells, CD8+ T cells and CD14+ 
monocytes. In the CD4+ and CD8+ T-cell subsets, we identified no differentially 
expressed non-MHC genes between HLA-DRB1 SE-positive and SE-negative 
individuals. In CD14+ monocytes, we identified six non-MHC genes that were 
differentially expressed between HLA-DRB1 SE-positive and SE-negative individuals. 
However, there were only ten CD14+ monocyte samples sequenced and the RIN value 
of most of these samples was relatively low. We therefore suggest that these findings 
should be first replicated in independent material before any conclusion is drawn. 
 
In CD4+ T cells, we found that the genes HLA-DRB4, HLA-DRB1, HLA-DQA2 and 
HLA-DQA1 had higher expression levels in healthy individuals carrying HLA-DRB1 
SE-positive alleles compared to SE-negative alleles. In CD8+ T cells, we found that 
HLA-DRB4 and HLA-DRB1 had higher expression levels in HLA-DRB1 SE-positive 
individuals, whereas HLA-DQB1 had higher expression levels in HLA-DRB1 SE-
negative individuals. In CD14+ monocytes, we identified the same differentially 
expressed genes as in CD4+ T cells. In addition, we found higher expression levels of 
HLA-A in CD14+ monocytes of HLA-DRB1 SE-positive versus SE-negative 
individuals. Taken the above-mentioned issues into account, we found the same genes 
to be differentially expressed in CD4+ and CD8+ T cells of HLA-DRB1*03:01/*04:01 
versus *03:01/*15:01 healthy individuals, although not statistically significant (Figure 
8). The small number of CD14+ monocyte samples, however, did not allow us to test 
differential expression in HLA-DRB1*03:01/*04:01 versus *03:01/*15:01 individuals. 
 
These results show that HLA-DRB and HLA-DQ genes are differentially expressed in 
all tested cell populations of healthy individuals carrying HLA-DRB1*04:01 versus 
*15:01 alleles. It has previously been shown that HLA-DRB1 gene expression levels in 
peripheral blood B cells were greatly influenced by HLA-DRB1 alleles311. However, 
the functional consequences of these differences in gene expression are to be 
discovered. In order to address functional consequences, it is critical to detect protein 
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levels of these genes as well. In addition, the function of HLA-DR in CD4+ T cells is 
still debated. Recent studies indicated that pathogenic T cells express HLA-DR in 
synovial fluid of RA patients312,313. In addition, HLA-DR expression on CD4+ T cells 
has also been proposed to be a marker of regulatory T cells314. Although these studies 
show that there are CD4+ T-cell populations that express HLA-DR, we cannot totally 
exclude the possibility that our results in CD4+ T cells are a reflection of the 
contamination by CD14+ monocytes. Moreover, as HLA-DRB1*04:01 is associated 
with RA, it will be interesting to measure HLA-DRB and HLA-DQ levels in sorted cells 
of RA patients with different HLA-DRB1 alleles. 
 
 
              
Figure 8. Differential expression of HLA-DRB1 in isolated cells of HLA-DRB1*04:01 versus 
*15:01 healthy individuals. A) Differential expression of HLA-DRB1 in CD4+ T cells of HLA-
DRB1*04:01 versus *15:01 individuals. B) Differential expression of HLA-DRB1 in CD8+ T 
cells of HLA-DRB1*04:01 versus *15:01 individuals. 
4.3.4 Concluding remarks 
We show that HLA-DRB1 and HLA-DQ genes are differentially expressed in all tested 
cell populations of healthy individuals carrying HLA-DRB1*04:01 versus *15:01 
alleles. These results suggest that the regulation of HLA-DRB and HLA-DQ gene 
expression could represent one of the mechanisms underlying the association of HLA-
DRB1 SE alleles to RA.  
 
4.4 PAPER IV: T-CELL TRANSCRIPTOMICS FROM 
PERIPHERAL BLOOD HIGHLIGHTS DIFFERENCES 
BETWEEN POLYMYOSITIS AND DERMATOMYOSITIS 
4.4.1 Rationale 
PM and DM are chronic inflammatory disorders clinically characterized by skeletal 
muscle weakness and muscle inflammation315. Inflammatory cell infiltrates are 
commonly found in the muscle of both PM and DM patients252,316. In patients with PM, 
the cellular infiltrates are typically dominated by CD8+ T cells272,317. In contrast, in 
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patients with DM, the cellular infiltrates are predominated by CD4+ T cells with 
occasional pDCs and B cells252. Although the T cell lineage is different between PM 
and DM, they both display a cytotoxic signature in the absence of the costimulatory 
CD28 receptor254,273. In addition, some of the identified genetic risk factors (e.g. 
PTPN22) are different between PM and DM184. These differences suggest that PM and 
DM are two different disorders. In this study, we addressed whether whole-genome 
transcriptomes of CD4+ and CD8+ T cells from peripheral blood were different 
between patients with PM and DM. 
4.4.2 Differential expression in CD4+ T cells 
We first focused on identifying differentially expressed genes in CD4+ T cells of 
patients with PM versus patients with DM. We found that the overall expression of 
genes in CD4+ T cells was very similar between PM and DM patients (examined by 
principal component analysis (PCA)). Using DESeq2283, we identified thirtheen genes 
that were differentially expressed between PM and DM patients. Among these genes, 
six were higher expressed in PM patients and seven were higher expressed in DM 
patients. However, the PCA plot indicated three potential outliers. By performing cell 
type enrichment analysis from gene expression data318, we found that these three 
samples have higher numbers of monocytes than the other samples. As described 
above, this is due to the isolation method (positive selection by CD4) we used. To 
exclude the possibility that the differentially expressed genes were detected because of 
a difference in cell composition, we excluded these samples and performed the analysis 
again. Four genes were found to be differentially expressed between PM and DM 
patients, two were higher expressed in PM patients and two were higher expressed in 
DM patients. We attempted to avoid false positive results by considering only genes 
that were found to be differentially expressed in both analyses (with and without 
potential outliers). This resulted in two genes, ANKRD55 and S100B, that were found 
to have higher expression levels in CD4+ T cells of PM patients compared to DM 
patients. The protein encoded by ANKRD55 is suggested to be involved in mediating 
protein-protein interactions319, however, the exact function is unknown. Interestingly, 
SNPs in the ANKRD55 locus have been found to be associated with several 
autoimmune diseases, including RA, Crohn’s disease and MS167,202,320-322. The protein 
encoded by S100B is involved in calcium-dependent regulation of a variety of 
intracellular activities323. S100B is normally not expressed in CD4+ T cells, but only in 
CD8+ T cells and NK cells324. This, in combination with low expression levels of 
S100B, might suggest either that the expression of S100B is evidence of contamination 
by other cell types or that this expression is a characteristic of CD4+ T cells in myositis 
patients. Although this data needs to be replicated in an independent group of myositis 
patients, we find that CD4+ T cell transcriptomes of patients with PM and DM are 
rather similar. 
 
The major genetic risk factor for myositis is HLA-DRB1*03. We therefore investigated 
which genes were differentially expressed in CD4+ T cells of HLA-DRB1*03-positive 
and HLA-DRB1*03-negative myositis patients. These subtypes of myositis patients 
were also not separated by the first principal components, suggesting that the overall 
expression of genes in CD4+ T cells was not different between HLA-DRB1*03-positive 
and HLA-DRB1*03-negative myositis patients. After performing both analyses (with 
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and without potential outliers), we identified six genes that were differentially 
expressed between HLA-DRB1*03-positive and HLA-DRB1*03-negative myositis 
patients. Among these genes, PI4KAP1 was found to have higher expression levels in 
HLA-DRB1*03-positive myositis patients and TRGC2, CTSW, HPCAL4, ZNF683 and 
GOLGA8B were found to have higher expression levels in HLA-DRB1*03-negative 
myositis patients. The protein encoded by CTSW (cathepsin W) is involved in antigen 
processing and is exclusively expressed in CD8+ T cells and NK cells325. The difference 
in CTSW expression levels might be due to contamination with other cell types, 
however, it might be possible that CTSW is expressed in CD4+ T cells of myositis 
patients but not translated into proteins. The protein encoded by ZNF683 is involved in 
the transcriptional regulation of effector functions, such as production of IFN-g and 
granzyme B326,327. Moreover, ZNF683 has been found to be upregulated in T cells with 
cytotoxic characteristics328. In addition to CD4+ T cells, we found higher levels of 
ZNF683 in CD8+ T cells of HLA-DRB1*03-negative myositis patients compared to 
HLA-DRB1*03-positive myositis patients (as discussed in the next section). 
4.4.3 Differential expression in CD8+ T cells 
We then focused on identifying differentially expressed genes in CD8+ T cells of 
patients with PM versus patients with DM. For the CD8+ T-cell samples, the patients 
with PM were all HLA-DRB1*03-positive and the patients with DM were all HLA-
DRB1*03-negative. The PCA plot showed no clustering of patients with PM and DM, 
suggesting that the overall gene expression in CD8+ T cells of patients with PM and 
DM is similar. However, we identified 588 genes that were differentially expressed 
between patients with PM and DM. Among these genes, 182 were higher expressed in 
PM patients and 406 were higher expressed in DM patients. We found that one of the 
CD8+ T cell samples was clustering with the CD4+ T cell samples in the overall 
analysis. We therefore excluded this sample and performed the differential expression 
analysis again. We now identified 308 genes that were differentially expressed between 
patients with PM and DM. Among these genes, 107 were higher expressed in PM 
patients and 201 were higher expressed in DM patients. By considering only the genes 
that were differentially expressed in both analyses (with and without potential outlier), 
we identified 176 genes that were differentially expressed between patients with PM 
and DM. Among these genes, 44 were higher expressed in PM patients and 132 were 
higher expressed in DM patients. For these 176 genes, the enriched Gene Ontology 
biological processes included lymphocyte migration and regulation of T-cell 
differentiation (Figure 9). In addition, we noted that the expression of two granzyme 
encoding genes, GZMH and GZMB, was higher in CD8+ T cells of DM patients 
compared to PM patients. It has been shown that the secretion of granzyme B by 
CD28null T cells may cause muscle cell damage273. Moreover, granzyme B cleavage 
sites have been identified in autoantigens, such as FHL1 and HisRS, which are targeted 
in myositis329,330. 
 
TGFB1, the transcript of one of the predominantly reported cytokines (TGF-b) in 
myositis331, had a higher expression in CD8+ T cells of DM patients compared to PM 
patients. Moreover, ZEB2, which encodes a TF that plays a role in TGF-b signaling, 
also had a higher expression in DM patients compared to PM patients. It has been found 
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that ZEB2 promotes CD8+ T-cell differentiation in response to viral infection332,333. 
ZEB2 is able to interact with SMAD proteins, which are the main signal transducers 
for receptors of TGF-b334. In our data, SMAD7 had a higher expression in DM patients 
compared to PM patients. Together, this may suggest that TGF-b signaling is 
upregulated in CD8+ T cells of DM patients compared to PM patients. 
 
 
Figure 9. The top 10 biological processes identified by Gene Ontology analysis of the 
differentially expressed genes in CD8+ T cells of PM and DM patients (sorted by fold 
enrichment). Bars represent the number of genes higher expressed in patients with PM (black) 
and higher expressed in patients with DM (white). Fisher’s exact test with false discovery rate 
correction was used to determine significant biological processes. 
 
We also found two TCR beta variable genes, TRBV28 and TRBV30, with higher 
expression in CD8+ T cells of PM patients compared to DM patients. TRBV28 has 
been found to be one of the most common TCR variable segments in muscle tissue of 
myositis patients carrying HLA-DRB1*03 alleles335. As mentioned above, all PM 
patients are HLA-DRB1*03-positive and all DM patients are HLA-DRB1*03-negative, 
suggesting that these genes are probably differentially expressed due to the HLA status 
of these patients. In addition, differential expression of these genes might reflect the 
expansion of pathogenic T-cell clones in this subset of patients. 
4.4.4 Concluding remarks 
We observed significantly more differentially expressed genes in the CD8+ T-cell 
subset than in the CD4+ T-cell subset when comparing PM versus DM patients. 
Although this data needs to be replicated in a bigger independent cohort of patients with 
PM and DM, it suggests that immune mechanisms related to CD8+ T cells may 
significantly vary between patients with PM and DM. It also emphasizes that CD8+ T 
cells are of general interest when studying PM and DM. 
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5 CONCLUSIONS AND FUTURE PERSPECTIVES 
 
Over the years, many susceptibility loci for autoimmune diseases have been identified, 
however, the functional mechanisms behind these associations are lacking. As the title 
‘gene expression profiling in autoimmune diseases’ suggests, this thesis aimed on 
creating a better understanding of the functional role of genetic risk factors in the 
development of RA and myositis by focusing on alterations in gene expression. 
 
Genetic variants in the PTPN2 locus have been found to be associated with several 
autoimmune diseases, including RA. Although PTPN2 might play an important role in 
autoimmunity, the exact mechanisms by which these genetic variants influence PTPN2 
are not clear. In Paper I, we found that genetic variants in the PTPN2 locus are 
associated with the expression of the lncRNAs LINC01882 and RP11-973H7.1, but not 
with the expression of PTPN2, in both healthy individuals and RA patients. By 
silencing LINC01882 in Jurkat T cells, we suggest that LINC01882 might play a role 
in T-cell activation by regulating IL-2 levels, an important cytokine in autoimmunity. 
This is one of the few examples that shows that genetic variants in intronic regions do 
not necessarily affect the closest gene. It will be of interest to study the function of the 
lncRNA RP11-973H7.1 in the context of RA as well. Our findings suggest the 
importance of these lncRNAs in other autoimmune diseases that were previously 
identified to be associated with genetic variants in the PTPN2 locus. 
 
In Paper II, we focused on understanding the functional role of a genetic variant 
(rs2476601) in the coding region of another member of the protein tyrosine phosphatase 
non-receptor family, namely PTPN22. PTPN22 is recognized as the second most 
important risk locus (after HLA-DRB1) for ACPA-positive RA. The functional impact 
of this genetic variant is not fully understood, as studies have described contradictory 
functions. We found that the presence of the PTPN22 risk genotype does not result in 
TCR blunting in naïve CD4+ T cells of healthy individuals. Instead, we found specific 
changes in expression of genes related to T-cell survival (CFLAR) and cytotoxic T-cell 
differentiation (TNFRSF9). This led us to identify an increased frequency of 
EOMES+CD4+ T cells in healthy individuals carrying the PTPN22 risk genotype. 
Although the exact mechanism is still to be discovered, we show a new role for the 
PTPN22 risk allele in the context of RA through the generation of CD4+ T cells with 
cytotoxic characteristics. In addition, there are several lncRNAs encoded on the 
PTPN22 locus. It will be interesting to study whether the PTPN22 risk allele is 
associated with the expression of these lncRNAs. It might be possible that these 
lncRNAs influence the levels of the TF EOMES in CD4+ T cells of PTPN22 risk allele 
carriers. 
 
The MHC class II gene HLA-DRB1 is the major genetic susceptibility locus for RA. 
Among others, the HLA-DRB1*04:01 allele is associated with ACPA-positive RA and 
is proposed to reflect a favored binding of citrullinated peptides to the binding groove 
of the HLA-DR beta chain. In Paper III, we studied differences in gene expression 
between healthy individuals carrying RA related HLA-DRB1 risk and non-risk alleles. 
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In PBMCs, CD4+ T cells and CD8+ T cells, we found no differentially expressed non-
MHC genes between individuals carrying HLA-DRB1*04:01 and *15:01 alleles. 
However, we identified a difference in the expression of HLA-DRB and HLA-DQ genes 
between individuals carrying HLA-DRB1*04:01 and *15:01 alleles. These differences 
in gene expression were observed in PBMCs, as well as in CD4+ T cells and CD8+ T 
cells. It will be of interest to study the protein levels of HLA-DR beta chains in 
individuals carrying different HLA-DRB1 alleles. This data suggests that HLA-DRB1 
and HLA-DQ levels, and potentially their corresponding proteins, might support loss of 
immune tolerance in RA patients carrying HLA-DRB1*04:01 alleles. 
 
In Paper IV, we studied differentially expressed genes between patients with PM and 
DM to differentiate involvement of CD4+ and CD8+ T cells in these myositis 
subgroups. In CD4+ T cells, we identified that the genes ANKRD55 and S100B had 
higher expression levels in patients with PM than in patients with DM. In CD8+ T cells, 
176 genes were differentially expressed in patients with PM compared to patients with 
DM. Although these results need to be confirmed in a larger group of patients, several 
differentially expressed genes between patients with PM and DM were related to 
cytotoxic T cells. These results add to the evidence that different immune mechanisms 
are involved in patients with PM compared to patients with DM. Interestingly, the 
genetic variant in the PTPN22 locus is also associated with PM but not with DM. 
Therefore, it will be interesting to study EOMES+CD4+ T cells in patients with PM 
and DM. 
 
 
Figure 10. Schematic overview of potential immune mechanisms in subgroups of RA and myositis 
patients. 
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My studies highlight the importance of using specific cell subsets instead of whole 
blood to study the mechanisms of disease-associated genetic variants. However, most 
of the cell types we studied were obtained from peripheral blood, which might not 
exactly reflect the cell types in the disease affected tissues. In addition, we collected for 
the first three studies healthy individuals with certain risk alleles to be able to separate 
genotype effects from phenotype effects. This resulted in the identification of new 
molecular pathways in RA patients with certain risk alleles. Finding the exact factors 
that drive the process of cytotoxic CD4+ T cell proliferation and differential expression 
of HLA-DRB1 and HLA-DQ genes is expected to lead to the identification of new 
therapeutic targets for personalized medicine. Promising therapeutic targets might be 
disease-related lncRNAs, such as LINC01882. In addition, the increasing evidence that 
different immune mechanisms are involved in subgroups of myositis patients, highlight 
the need for specific treatments for PM and DM. Further studies are needed to conclude 
if some of the identified differentially expressed genes might be useful for therapeutic 
development. 
 
Overall, we identified new molecular pathways for genetic risk variants in the PTPN2, 
PTPN22 and HLA-DRB1 loci in the context of RA and other autoimmune diseases. We 
suggest that different immune mechanisms are involved in subgroups of RA and 
myositis patients (Figure 10). These results could ultimately lead to the identification 
of new therapeutic targets for different autoimmune diseases. 
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